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This report represents a summary of presentations at a joint workshop of the National Institutes of
Health and the American Association of Physicists in Medicine ~AAPM!. Current methodological
issues in dose–volume modeling are addressed here from several different perspectives. Areas of
emphasis include ~a! basic modeling issues including the equivalent uniform dose framework and
the bootstrap method, ~b! issues in the valid use of statistics, including the need for meta-analysis,
~c! issues in dealing with organ deformation and its effects on treatment response, ~d! evidence for
volume effects for rectal complications, ~e! the use of volume effect data in liver and lung as a basis
for dose escalation studies, and ~f! implications of uncertainties in volume effect knowledge on
optimized treatment planning. Taken together, these approaches to studying volume effects describe
many implications for the development and use of this information in radiation oncology practice.
Areas of significant interest for further research include the meta-analysis of clinical data; inter-
institutional pooled data analyses of volume effects; analyses of the uncertainties in outcome pre-
diction models, minimal parameter number outcome models for ranking treatment plans ~e.g.,
equivalent uniform dose!; incorporation of the effect of motion in the outcome prediction; dose-
escalation/isorisk protocols based on outcome models; the use of functional imaging to study radio-
response; and the need for further small animal tumor control probability/normal tissue complica-
tion probability studies. © 2002 American Association of Physicists in Medicine.
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The rapid advance and acceptance of three-dimensional con-
formal radiation therapy and intensity modulated radiation
therapy is revolutionizing the delivery of radiation therapy.
Despite this development, the ability to evaluate and com-
pare the resulting highly complex dose distributions with re-
spect to expected clinical outcomes has lagged far behind.
One major factor has been the lack of useful data available to
assess and develop useful predictive models. A second major
factor is the need for new plan-ranking methods that corre-
late inherently multidimensional dose distribution data with
outcomes. This report represents a summary of presentations2109 Med. Phys. 29 9, September 2002 0094-2405Õ2002Õ2at a joint workshop of the National Institutes of Health and
the American Association of Physicists in Medicine ~AAPM!
held in Bethesda, Maryland, 22 October 1999. It is the first
publication of the Biological Effects Committee Task Group
8, Volumetric Tissue Response Models in Radiation Oncol-
ogy, organized by the Biological Effects Committee of the
AAPM. Volume effect issues are addressed here from several
different perspectives. The topics discussed include ~a! basic
modeling issues including the equivalent uniform dose
framework and the bootstrap method, ~b! issues in the valid
use of statistics, including the need for meta-analysis, ~c!
issues in dealing with organ deformation and its effects on210999Õ2109Õ19Õ$19.00 © 2002 Am. Assoc. Phys. Med.
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clinical site ~rectum!, ~e! the use of volume effect data in
liver and lung as a basis for dose escalation studies, and ~f!
implications of uncertainties in volume effect knowledge on
clinical practice. The presentations and references were up-
dated for publication. Taken together, these approaches to
studying volume effects describe many implications for the
development and use of this information in radiation oncol-
ogy practice.
II. MODELING THE EFFECT OF INHOMOGENEOUS
DOSE DISTRIBUTIONS
Andrzej Niemierko
Dose distributions in radiation therapy are inherently in-
homogeneous. This is due to the heterogeneity and geometry
of the irradiated tissues, and the physics of radiation beams
designed to deliver high dose to the tumor volume while
maximally sparing surrounding normal structures. The ad-
vent of three-dimensional treatment planning and, more re-
cently, Intensity Modulated Radiation Therapy ~IMRT! cre-
ated tools for planning, and means for delivering, optimized
dose distributions tailored to the patient’s geometry. The
IMRT dose distributions are often significantly different from
the corresponding dose distributions obtained using non-
modulated fields. Even when treatment planning is per-
formed according to a specific protocol the IMRT dose dis-
tributions can be also substantially different from case to
case, as a result of much greater flexibility available in IMRT
for plan individualization. However, this flexibility has also
some drawbacks. For example, optimized IMRT target dose
distributions sometimes have relatively deep cold spots, usu-
ally on the periphery of the target volume. The clinical ex-
perience with such dose distributions is limited, which makes
a quantitative comparison of rival plans more difficult.
To take full advantage of the available technology and to
optimize and individualize radiation treatment, one needs
tools to assess the potential clinical outcome of any radiation
treatment. That is, one needs tools that quantify the probabil-
ity of an end point of interest @e.g., Tumor Control Probabil-
ity ~TCP!, Normal Tissue Complication Probability ~NTCP!,
or five-year recurrence-free survival# as a function of deliv-
ered radiation treatment ~i.e., the volumetric and temporal
distribution of dose! and as a function of the most meaning-
ful characteristics of the irradiated tissues and organs ~i.e.,
their geometry and biology!. Of course, the response of any
biological systems to radiation is complex and multifaceted.
It is unfeasible to account for all the processes contributing
to the observed outcomes. However, we can try to identify
and model the dominant ones.
Since radiation directly kills cells, much effort has been
expended to investigate cell survival characteristics and to
develop models of tissue response to radiation based on the
so-called ‘‘target cell hypothesis.’’ 1,2 By definition, the target
cells are those cells that are capable of replication and regen-
eration of the tissue. Hence, it is hypothesized that tissue and
organ response to radiation can be described in terms of the
survival probability of the target cells. Tissues and organsMedical Physics, Vol. 29, No. 9, September 2002differ in their target cell survival characteristics and their
organization. Consequently, tissues and organs differ in their
tolerances and their response to altered dose distributions
and fractionation. These differences have important implica-
tions for treatment planning and for optimization of radiation
therapy. For example, IMRT has the capability of ‘‘shaping’’
dose distribution by using a large number of individually
weighted ~modulated! ‘‘beamlets.’’ This capability allows
partial sparing of the sensitive critical structures surrounding
the target volume while still delivering a high dose to the
tumor. Obviously, to optimally distribute unavoidable dose to
critical normal structures and to quantify the difference be-
tween competing dose distributions one needs quantitative
models of dose–volume and dose–response relationships for
all structures of interest.
The fundamental requirement for any dose optimization
process is to be able to rank the competing dose distribu-
tions. That is, to be able to tell which dose distribution is
better. Note that for plan ranking it is unnecessary to know
by how much one plan is better than the other. The physical
dose is an easy-to-understand and convenient metameter of
radiation treatment planning. As a rule, more dose to the
target volume and less dose to the critical structures is con-
sidered to be better. However, because dose distributions are
three-dimensional inhomogeneous objects they cannot be
ranked directly. That is, it is meaningless to ask what dose
was actually delivered to a structure of interest if the dose
distribution within that structure is nonuniform.
A concept of Equivalent Uniform Dose ~EUD! was devel-
oped for more precise reporting, analyzing, and ranking dose
distributions actually delivered to irradiated organs and vol-
umes of interest.3 The concept of EUD assumes that any two
dose distributions are equivalent if they cause the same ra-
diobiological effect of interest. For example, for tumors it is
often postulated that the probability of local control is deter-
mined by the expected number of surviving clonogens, ac-
cording to Poisson statistics. Therefore, it can be shown that
for any inhomogeneous target dose distribution the EUD is
calculated as follows:
EUD52 Gy
lnF 1N ( i51N ~SF2!Di/2 GyG
ln~SF2!
, ~1!
where SF2 is the fraction of clonogens surviving a dose of 2
Gy and the sum is taken over all N dose calculation points
within the target volume and Di is the dose at point i. Using
the formalism of the Linear–Quadratic model but suppress-
ing the quadratic component for simplicity here ~see Ref. 3
for the more complex equation which results if the quadratic
component is included! the EUD is calculated as follows:
EUD52
lnF 1N ( i51N exp~2aDi!G
a
, ~2!
where a is the initial slope of the survival curve.
It is important to recognize that the EUD formalism ex-
pressed in Eqs. ~1! and ~2! represents a situation where both
dose distributions, i.e., the original inhomogeneous one and
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number of fractions with identical interfractional interval and
identical overall time. More generally, all nonvolumetric pa-
rameters of the treatment plan are constant.
There are several important consequences of the clonogen
survival-based EUD concept. ~1! The EUD for tumors is
always bounded by the minimum target dose and the mean
target dose. ~2! For greater dose inhomogeneity the EUD
tends toward the minimum target dose; for lesser inhomoge-
neity it tends toward the mean target dose. ~3! The detrimen-
tal effect of a cold spot is more pronounced for tumors char-
acterized by more sensitive clonogens ~i.e., lower SF2 or
higher a!. Reference 3 contains logical extensions of this
EUD model to account for absolute volume effect, dose per
fraction and proliferation effects, and possible nonuniform
spatial distribution of clonogens. It should be noticed that for
treatment plan optimization, the simple EUD model pre-
sented here with the parameter SF2 set to 0.5 is often suffi-
cient. The EUD concept has been demonstrated to be useful
for clinical data analysis4 and for optimization of IMRT.5
The EUD model can be extended to normal tissues based
on the concept of Functional Sub-Units ~FSUs!.6,7 It is hy-
pothesized that for most normal structures the outcome is
determined by the number or the fraction of the FSUs that
survive the treatment. Most normal organs exhibit some sort
of functional reserve that allows the organ to maintain its
functionality, even when some fraction of that organ is com-
pletely destroyed. Consequently, the FSU-based EUD model
exhibits the strongest dependence on the subvolume of the
irradiated organ that receives no or very little dose. The EUD
for normal structures is usually bounded by the mean and the
maximum dose to the structure of interest. This relationship
depends upon the survival characteristics of the hypothetical
FSUs and their organization. For example, for structures with
a ‘‘serial’’ organization ~spinal cord and esophagus are often
given as examples!, the EUD is closer to the maximum dose.
For structures with a ‘‘parallel’’ organization ~e.g., lung,
liver, kidney! the EUD is closer to the mean dose.8
The effects of dose inhomogeneity can be also accounted
for by using phenomenological models, such as the dose–
volume histogram reduction schemes based on the power
law.8–10 One can argue that it is practically impossible to
develop a comprehensive biological model of tissue response
to radiation and therefore these phenomenological ap-
proaches may present a better ~or at least less model-
dependent! choice. Based on the power law the EUD can be
calculated as follows:
EUD5S 1N (i51
N
Di
aD 1/a. ~3!
This EUD formula has been proposed for both tumors and
normal structures.8 The model parameter ‘‘a’’ is negative for
tumors and positive for normal structures. It is easy to see
that for large negative ‘‘a’’ the EUD tends to the minimum
dose and for large positive ‘‘a’’ the EUD tends to the maxi-
mum dose. For ‘‘a’’ equal to one the EUD represents the
average dose. The parameter ‘‘a’’ is tissue and end-point spe-Medical Physics, Vol. 29, No. 9, September 2002cific and the value of ‘‘a’’ needs to be obtained by fitting an
EUD-based dose-response model to clinical data.
It is difficult to differentiate and validate either biology-
based or phenomenology-based models using statistically ad-
equate methods because the available clinical data are usu-
ally incomplete and too weak. On the other hand, because
the data are weak it is often possible and easy to ‘‘fit’’ them
with a wrong model. That is, the data may be too weak to
reject a bad model. Nevertheless, if cautiously used either
model can provide helpful quantitative measures for evaluat-
ing dose distributions.
A logical consequence of the concept of EUD is to use it
as a sole argument of the models of tissue response to radia-
tion. This is because all the relevant effects ~volumetric, tem-
poral, and others! can be accommodated within the concept
of EUD. Hence, the probability of effect to an end point of
interest can be estimated using the corresponding EUD and
any convenient dose-response function such as Logit, Probit,
Poisson, or exponential.11–13
III. USEFUL MODELS AND ADEQUATE
METAPHORS
Donald Herbert
‘‘All models are wrong, but some are useful.’’ G.E.P. Box,
1979.14
Quality of Care and the ‘‘Ethics of Belief:’’ In the field
of radiation oncology, AAPM Report 43 ~199315! describes
in detail, ‘‘...the statistical inadequacy of many historical and
contemporary studies which have been accepted as the basis
for the construction of models used in clinical practice. Use
of these flawed models may well have retarded progress in
the past and, more importantly, still threatens to inhibit fu-
ture advances in the practice of radiation oncology.’’—L.
Cohen, 1993,16 a finding with implications for the work of
Task Group 8 ~see below!.
These findings are quite consistent with other evaluations
of the quality of the medical literature, e.g., ‘‘Serious wide-
spread problems exist in the clinical literature...the average
practitioner will find relatively few journal articles that are
scientifically sound in terms of reporting usable data and
providing even moderately strong support for their
inferences.’’ 17 Such findings are disturbing in view of the
recent IOM report on the quality of health care.18 The Na-
tional Cancer Policy Board, in its 1999 publication, ‘‘Ensur-
ing Quality Cancer Care,’’ 19 used the IOM 1998 definition
of quality cancer care: ‘‘Health care can be judged as good
to the extent that it increases the likelihood of desired health
outcomes and is consistent with current professional
knowledge.’’ This has two immediate implications for the
work of AAPM Bioeffects Committee Task Group 8: First,
assessments of ‘‘desired health outcomes,’’ should include
psychometrically valid measures of the functional status of
the patient such as is provided by the MOS SF-36
questionnaire.20 The 1989 Patient Outcome Research Act21
mandated that measures of ‘‘functional status and well-being
and patient satisfaction’’ be included with traditional mea-
2112 Deasy et al.: Methodological issues in radiation dose-volume outcome analyses 2112sures of survival, clinical end points and disease. Functional
status measurements are important not only as ‘‘outcomes’’
for payers but also as covariates in models predicting clinical
‘‘outcomes.’’ Second, some investigators have incorporated
the LQ model into IMRT models. However, the LQ model is
inconsistent with ‘‘current professional knowledge:’’ AAPM
Report 43 holds the validity of the LQ model to be very
problematic. ~All models are wrong, but some are awful.!
Moreover, even if the validity of the model were less of a
problem, the estimates of the parameters, a, b, and their
ratio, a/b, are encumbered with large uncertainties, both ran-
dom and systematic @e.g., the ratio of estimates, est~a!/
est~b!, is a biased estimate of the ratio, a/b#, since, as re-
marked in AAPM Report 43, they tend to be constructed by
‘‘dubious methods from questionable data.’’ 15 This is, of
course, ‘‘A major problem in many areas...experts often hold
strong beliefs that have no evidential foundation. ... A key
problem about the ethics of belief is that people may believe
strongly in something they know little about and have little
evidence for,’’ F. Mosteller, 1999.22
Meta-analysis: ‘‘Meta-analysis is going to revolutionize
how the sciences, especially medicine, handle data. And it’s
going to be the way many arguments will be ended.’’ T.
Chalmers, 1991.23 Meta-analysis is a statistical method for
combining the information residing in the summary statis-
tics, say odds ratios and their standard errors, from a group
of independent studies, e.g., clinical trials, of a given treat-
ment or diagnostic procedure. In biomedical and epidemio-
logical investigations it is usually undertaken to achieve one
of two aims: ~1! obtaining pooled point and interval esti-
mates of an overall ‘‘true treatment effect.’’ ~2! ‘‘borrowing
strength’’ across a group of studies to obtain improved point
and interval estimates of the effect in each study, i.e., im-
proved study-specific estimates.24 There are four models of
meta-analysis: fixed effects, random effects, mixed effects,
and Stein effects. The first three models are used to achieve
the first aim. The last two are used to achieve the second aim.
The Stein, or empirical Bayes model, like most Bayes mod-
els, provides a useful answer to the extrapolation problem
often described as Bernard’s dilemma: The response of the
‘‘average’’ patient to therapy is not necessarily the response
of the patient being treated.
However, although meta-analysis was initially introduced
as a bridge across the gap between undersized controlled
trials and the treatment of patients, given the current state of
the literature remarked above, it may be equally ~or more!
useful as a filter: ‘‘Meta-analysis ... spotlights the ... grave
defects in the majority of original research that only come to
light if an attempt is made to combine the data with that of
other research.’’ T. Chalmers, 1987.25 ~Such findings deter-
mined the direction of AAPM Report 43.!
Validated reviews: As a remedy for the poor quality of
the medical literature described above, it is recommended
that the ‘‘average practitioner seek reviews based on vali-
dated research sources.’’ 17 The best such reviews are those
of the Cochrane Collaboration. The Cochrane Collaboration
is a nonprofit international organization that produces high
quality systematic reviews ~where possible meta-analyses! ofMedical Physics, Vol. 29, No. 9, September 2002all studies, both published and unpublished, of every sort of
health care intervention.26 These are subjected to rigorous
evaluation and regularly updated. The results of these re-
views are regularly disseminated electronically both on CD
ROM and via the Internet. Physicians and scientists seeking
the best evidence either to guide their practice or to design
their studies will more likely find it in the systematic reviews
of the Cochrane Collaboration than in the unaggregated and
‘‘unfiltered’’ studies listed on MEDLINE or EMBASE. Nay-
lor has remarked that, ‘‘... the Cochrane Collaboration is an
enterprise that rivals the Human Genome Project in the po-
tential implications for modern medicine.’’ 27
Clinical databases: Clinical databases are a crucial com-
ponent in the useful extrapolation of the results of clinical
trials to local clinical practice since ~1! ‘‘Clinical trials are
typically done under carefully controlled circumstances in a
university setting and do not reflect the use of a technology in
community practice’’ 28 and ~2! ‘‘Patients in a trial are not
to be regarded as a random sample from some
population.’’ 29 Indeed, ‘‘Data on the quality of community
practice by hospital and physician are essential for making
proper use of data from randomized trials ... the quality with
which each arm of the trial may be carried out in the com-
munity may overwhelm any differences between alternative
therapies that are demonstrated in the trial itself.’’ R. Brook,
1993.30 ~Unfortunately, at present, most clinical databases
are inadequate to support useful extrapolations.!
Databases also should be considered for use both as a
supplement to randomized clinical trials in ensemble-of-
studies models, as in the meta-analytic procedure of Cross-
Design Synthesis31 and in Response Surface Designs ~see
below! and as an alternative to them. In the usual meta-
analysis, it is common to pool the summary statistics ~e.g.,
the odds ratio and its standard error! of a set of studies en-
cumbered by common weaknesses. In the case of clinical
trials these may be high levels of type I and type II errors. In
Cross-Design Synthesis the summary statistics of a set of
studies with complementary weaknesses are pooled. Thus,
clinical trial results with characteristic low external validity
~since patients in the trial are not randomly selected!29 are
pooled with database results with characteristic low internal
validity ~since rival treatments are not randomly assigned!.
Volume effects: Typically there are four categorical out-
comes to any treatment of a cancer patient: These are the
compound events, E1 and E¯ 2 , E¯ 1 and E¯ 2 , E1 and E2 , E¯ 1
and E2 , where E1 is ablation of tumor, E2 is the complica-
tion of normal tissue ~‘‘No side effect, no effect’’! and the
overbar identifies the complementary event. Then treatment
success is the event S5E1 and E¯ 2 . Treatment failure is the
complementary event S¯5E1 and E2 or E¯ 1 and E2 or E¯ 1 and
E¯ 2 .32–34 It is the joint probabilities, say P~E1 and E¯ 2!, of
compound events that are of interest and since the elemen-
tary events ~E1 , E2 , etc.! are not independent, a bivariate
probit dose-response model35 is most useful. Models of the
joint probability of the occurrence of compound events are
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dation of ‘‘volume effects’’ and ~2! the design of clinical tri-
als.
Describing the outcome of treatment in terms of the com-
pound events S5(E1 and E¯ 2) provides a useful insight into
two of the effects of volume of irradiated tissue on the prob-
ability of occurrence of this event. Herbert34 ~1984! showed
that his 1983 ‘‘extreme value’’ model33 of volume effects in
radiation oncology ~based on the Statistical Theory of Ex-
treme Values that has proved so useful in explaining the ef-
fects of a cognate ‘‘size effect’’ on the strength of materials in
engineering studies! predicts ~1! that the probability of un-
complicated control of a tumor decreases as the volume in-
creases and ~2! that the slopes of the respective dose re-
sponse curves for ablation of tumor and complication of
normal tissue increase as the volume of irradiated tissues
increase. Empirical observation strongly suggests that radia-
tion complication in normal tissue is a smallest value phe-
nomenon and that the recurrence of a tumor is a largest value
phenomenon, i.e., ‘‘chain’’ ~series connection! and ‘‘rope’’
~parallel connection! models, respectively.33
Figure 1 shows the density functions of smallest and larg-
est values of a two parameter Weibull distribution.34 It shows
that as the sample size ~volume! increases, the separation
between the respective density functions increases: the
smallest values get smaller, the largest values get larger, ex-
actly what would be expected if x were a measure of the
‘‘breaking strength’’ of the tissue, either normal or tumor.
This is the level of ambient ‘‘stress’’ at which the functional
and/or structural integrity of the tissue fails. For example, for
tumor tissue the ‘‘stress’’ may be the immunocompetence of
the host, cytotoxic drugs, etc.; for normal tissue, the ‘‘stress’’
may be physical trauma such as a blow, low temperatures,
etc. Figure 2 shows a superposition of the dose-response
curves for ablation of tumor, P(E1ux1), and necrosis of nor-
mal tissue, P(E2ux1), at T545 days and N533 fractions for
FIG. 1. A superposition of the density funcion of a two-parameter ~location
and scale! Weibull distributions, f (x), and the density functions of the
smallest, gi(x (1)), and largest hi(x (n)) , values of x in samples of size n from
the parent distribution, f (x). The mode of the distribution of smallest ~larg-
est! values decreases ~increases! with sample size n , e.g., n is larger for
g2(x (1)! than for g1(x (1)).Medical Physics, Vol. 29, No. 9, September 2002target volumes V1 ~solid! and 2V15V2 ~dashed! in carci-
noma of the oropharynx.21 Note that the location and scale
measures of both dose-response curves are functions of the
target volume, V . Note that the location of P(E1ux1) is
shifted to lower doses as V increases. Note that the slope of
each dose-response increases as V increases.
Response surface designs: Clinical trials are commonly
designed to test hypotheses on the levels of a response vari-
able, e.g., survival, in comparing two or more interventions.
However, in Response Surface Designs ~RSD!, one is inter-
ested, instead, in finding, by a Steepest Ascent method, the
set of values of the treatment variables that yield a maximum
response, typically, the maximum probability of uncompli-
cated control of disease, a treatment success: P(S). RSD is
an iterative, evolutionary, extrapolation procedure that con-
structs polynomial models of second order in the treatment
variables ~‘‘useful models’’! to a set of dose-response data. It
identifies the local nature of the resulting surface ~ridge,
maximum, saddle, etc.! by the sign and size of the eigenval-
ues of the canonical quadratic form of the surface and if the
eigenvalues are not all negative, and of roughly the same
size, the corresponding eigenvectors give an estimate of the
direction to the maximum.35 ~See Herbert 199736 for a heu-
ristic exposition of clinical RSDs.! Figure 3 gives the layout
and analysis of a typical RSD in two variables: elapsed time
T and total dose D of radiation for treatment of cancer of the
oropharynx. The dashed lines identify a family of isoeffect
curves for P(S), the probability of uncomplicated control.
The constructed response surface is an ellipse; the signs and
relative sizes of the eigenvalues suggest that the response
surface in this region is a ‘‘ridge’’ rising in a direction given
by the eigenvector shown.
Data mining: Randomized controlled clinical trials are
FIG. 2. A superposition of the dose–response curves for ablation of the
tumor, P(E¯ 1ux1), and necrosis of normal tissue, P(E2ux1), at T545 days
and N533 fractions for traget volumes V1 ~solid! and 2 V15V2 ~dashed!.
Note that the location of the curve P(E2ux1) is shifted to higher levels of
dose x1(5log D) and P(E2ux1) is shifted to lower levels of dose x1. The
slope of both dose–responese curves is also increased as the volume, V ,
increases.
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structed on dose–response data obtained in a response
surface design ~points 1–9! in the region of D–T treat-
ment space in which the response, P(S), varies with
treatment, (D ,T), along a ‘‘rising ridge.’’expensive in terms of time, effort, and money, and in the case
of rapidly changing technology such as IMRT, their inherent
low levels of external validity are further reduced by the
passage of time so that the results at the end of the trial are
often irrelevant to any current practice. They are also fraught
with serious ethical problems. However, databases have, in
principle, inherently high levels of external validity and raise
few ethical issues.37 Moreover, major advances in technol-
ogy have provided the ability not only to create huge data
stores ~e.g., terabytes of data! but also the ability to extract
high levels of information therefrom for prediction, for deci-
sion, and for understanding. This latter ability, loosely called
‘‘data-mining,’’ or, more precisely, knowledge discovery in
databases ~KDD! is a new field of statistics directed to the
discovery of useful and often unsuspected patterns hidden
deep within the data base and embedded in high-dimensional
spaces.38
Nonlinear dynamics: Some investigators in the biomedi-
cal field have recently come to realize that, ‘‘The human
body is an exceedingly complex mosaic of nonlinear dynami-
cal systems. ... A detailed understanding of the dynamics of
such systems must necessarily be carried out in the context of
the mathematics of nonlinear systems.’’ L. Glass, 1991.39 For
example, several biological phenomena of particular impor-
tance to radiation oncology—‘‘jumps,’’ thresholds, oscilla-
tions, bistability and birhythmicity, emergence and self-
organization—are unique to nonlinear systems. Moreover, in
nonlinear systems, output is not only not simply proportional
to input but may be qualitatively different from it, i.e.,
‘‘More is different.’’ P. Anderson, 1987,40 a potential problem
in dose-escalation studies. Anderson’s aphorism asserts that
nonlinear phenomena are physically scale dependent, i.e.,
there is an inherent ‘‘volume effect’’ in nonlinear dynamical
systems.
Models and metaphors: Useful models of empirical data
on outcomes must be statistical; in particular, they must be
generalized linear models ~e.g., logit, probit, Normal, Pois-
son, etc.! constructed with the aid of Bayesian methods andMedical Physics, Vol. 29, No. 9, September 2002regression diagnostics and sensitivity analyses on data ob-
tained from well-designed experiments ~especially factorial!
and surveys ~of databases!.15,41,42 However, useful models of
theoretical constructs that inform the designs must be dy-
namical; ~dynamics: the study of how the state of a system
changes in time! in particular, causal models must be de-
scribed as nonlinear dynamical systems ~sets of coupled non-
linear differential equations, both ordinary and partial! and
understood in terms of the attractor-basin-bifurcation
metaphors of nonlinear dynamics.43
In contemplating the great promise that IMRT seems to
offer to the practice of radiation oncology, it is useful to
recall that, ‘‘Every important scientific advance that has
come in looking like an answer, has turned, sooner or later—
usually sooner—into a question.’’ L. Thomas, 1983.44
IV. DOSE–VOLUME-OUTCOME ANALYSIS: SOME
NEW METHODS AND OPEN CHALLENGES
Joseph O. Deasy
Increasing the effectiveness of radiation therapy depends
on improving our understanding of dose–volume factors af-
fecting tolerance and local control. We briefly discuss some
new methodologies for analyzing dose–volume effects, and
some challenging open problems in this interesting field of
research.
New treatment principles may emerge from a deeper un-
derstanding of dose–volume tumor and normal tissue re-
sponse. What dose distributions are most desirable? For
gross disease, initial theoretical studies by us, Goitein et al.,
and Tome and Fowler, indicate that boosting a fraction of the
gross tumor volume (GTV) could significantly increase local
control.45–48 The theoretical arguments and calculations can
be summarized as indicating that: partial tumor boosts of
more than 10–15 Gy would be expected to eliminate ~nearly!
all recurrences in which disease recurs in the boosted volume
only ~and not in the nonboost volume!. The resulting dose
response curve is expected to be nearly equivalent to that
2115 Deasy et al.: Methodological issues in radiation dose-volume outcome analyses 2115which would hold for the same tumor but of a reduced vol-
ume equal to the nonboost gross tumor volume.46 It is not the
goal, of course, to give a reduced dose to part of the tumor,
but these considerations support the use of a partial volume
boost when a part of the tumor must be given reduced dose,
due to constraints from nearby normal tissues. Very few
clinical tests of theoretical ideas regarding TCP have been
published to date,49–51 but this is expected to change with the
widespread implementation of 3-D treatment planning. How-
ever, as pointed out elsewhere in this report by Ten Haken
and Yan, dosimetric ‘‘corruption’’ due to positioning errors
may need to be controlled or otherwise taken into account to
accurately model TCP, especially as TCP is expected to be
highly sensitive to even small cold spots.
It has also been shown that the effect of hot or cold spots
on TCP depends on the underlying model assumptions con-
cerning interpatient and intratumor radiosensitivity
heterogeneity.52 In general, TCP models that neglect interpa-
tient variations in radiosensitivity, yet still try to fit dose
response curves by positing a small number of resistant
clonogens, are less sensitive to cold spots. A further compli-
cating factor is the likely existence of variations in the intra-
tumor radiosensitivity heterogeneity distribution between pa-
tients. Attempts to reconcile mechanistic TCP models with
measured in vitro surviving fractions at 2 Gy (SF2), using
tumor biopsy material, have shown a discrepancy.52 Theoret-
ical predictions of the steepness of local control curves were
carried out using a TCP model based on Poisson cell kill and
laboratory measured SF2 coefficients of variation ~typically
40%!. Over a wide range of possible parameter values, in-
cluding wide variations in mean tumor radiosensitivity, the
TCP model using in vitro SF2 coefficient of variation data
~i.e., coefficients of variation of 35%–45%! predicted far
shallower local control curves than those clinically observed.
The inclusion of any other type of heterogeneity in the TCP
model, such as clonogen number interpatient heterogeneity,
would only make predicted dose-response curves more shal-
low and therefore worsen the disagreement. The only sug-
gestion thus far to reconcile this fundamental disagreement is
that the number and radiosensitivities of the more radiosen-
sitive clonogens within a tumor ~those that tend to affect SF2
the most! varies more between patients than the number and
radiosensitivities of the most resistant clonogens ~those that
are more likely to affect the clinical outcome!.52 Partial sup-
port for this idea is supplied by the results of Britten et al.,53
who measured the intratumor heterogeneity distribution for
three cervical uterine carcinoma patients, and observed intra-
tumor heterogeneity distributions similar to those hypoth-
esized in Ref. 52. More measurements of intratumor hetero-
geneity for a greater number of patients would be needed to
resolve this conflict. Such investigations are needed to place
models of TCP, and consequently their clinical predictions,
on a more reliable footing. Another important source of tests
for TCP models could potentially be small animal experi-
ments, using nonuniform but well-characterized doses of ra-
diation to explanted xenografts.
The biological assumptions that should go into math-
ematical predictions of normal tissue complication probabili-Medical Physics, Vol. 29, No. 9, September 2002ties ~NTCPs! are far more tenuous than those for TCP, and
therefore we expect to rely mainly on clinical data and
simple descriptive models with few a priori assumptions.
The present uncertainties in model assumptions and pa-
rameter values for dose–volume models are, of course, a
significant barrier to clinical use of the models. This is
mainly the result of the lack of high-quality clinical data for
which the dosimetry is accurate and the outcome data is
available, but there are also important open issues with re-
spect to data analysis. Once a ‘‘good’’ dataset has been es-
tablished for a given toxicity end point, it will, as usual, be
important to understand the relative uncertainty of model fits
to measured data. One very flexible method for estimating
model parameter uncertainties is the bootstrap technique.54
This method is based on the idea that a multidimensional
histogram of the actual set of patient data, including out-
comes, can be used as an approximation of the probability of
collecting similar data in a future trial. One can then draw
random samples from the present collection of data to form
pseudoclinical datasets. A pseudoclinical dataset will typi-
cally include multiple copies of the data from one or more
patients, by chance. The fitting process is then applied to
each pseudoclinical dataset to derive the fitted parameters.
This sampling–fitting process is repeated many times ~typi-
cally several hundred to a thousand times! and results in an
approximate probability distribution of the fitted parameter
values ~assuming, of course, that the model is capable of
fitting, or describing, the data!, given the observed input
data. As an example, we have applied the bootstrap tech-
nique to analyze the reduction of saliva due to parotid gland
irradiation.55 Figure 4 shows saliva data ~stimulated by
chewing! at six months post-radiation therapy, plotted as a
function of the left and right parotid mean doses. For didactic
purposes we consider the simple model ~other models ulti-
mately fit the data better!:
f 5 12NR (i51
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where f is the predicted saliva level after treatment relative to
FIG. 4. Relative stimulated saliva measured six months after the end of
radiation therapy, plotted as a function of mean doses to the left and right
parotid salivary glands.
2116 Deasy et al.: Methodological issues in radiation dose-volume outcome analyses 2116pretreatment, a is a radiosensitivity parameter, N refers to the
number of equivolume voxels in the left and right parotids,
and the di are the voxel doses with the additional subscript
indicating a left or right gland. This is a very simple FSU-
type model, because the basic assumption is that functional
contributions are independent from voxel to voxel. The only
fitting parameter is a. Figure 5 shows the bootstrap results
and thereby indicates how a could reasonably be expected to
vary for other samples of the patient population.
It will be important to propagate the uncertainties inherent
in the model parameter estimates into the final estimates of
TCP/NTCP or another predicted outcome ~such as the saliva
level!, so that error bars are available as part of the treatment
planning process. We have developed a technique for incor-
porating data uncertainties into outcome estimates, which
also uses the bootstrap method.56 Instead of computing TCP,
NTCP, or some other outcome measure using just the maxi-
mum likelihood fitted parameters, we compute outcome es-
timates for the entire list of bootstrap determined sets of
parameters. Again, this list is considered to be a surrogate for
the probability distribution that a given parameter set is cor-
rect. Loss of saliva function ~say! would be computed for
each of the bootstrap parameter determinations. The list of
predicted saliva levels could be used to put error bars around
the estimate of predicted saliva level.
For outcomes that are defined as probabilities ~such as
TCP and NTCP!, we suggest that it is actually more funda-
mentally correct to average TCP/NTCP over all the results
based on bootstrap resampling parameters, or some other
method of estimating parameter probabilities. This would
give a more faithful estimate of the actual TCP or NTCP,
because we really do not know which model parameters are
‘‘correct.’’ The minimum of the likelihood surface for the
FIG. 5. Shows a histogram of 500 bootstrap resampling determinations of
the fitted parameter a for Eq. ~4!. The bootstrap results are instructive, es-
pecially when distributions are non-Gaussian, as is the case here. Non-
Gaussian distributions are common when a parameter value has a natural
lower limit ~such as zero! and the coefficient of variation is of the same
order of magnitude or larger than the mean value. The bootstrap histogram
can be used to determine confidence limits. Further analyses included a
quadratic dose term ~see Ref. 9!.Medical Physics, Vol. 29, No. 9, September 2002original dataset is typically broad, and it follows that model
parameters that significantly deviate from the maximum like-
lihood values have some probability of being more correct in
reality.
This bootstrap-uncertainty method will not, of course, ad-
dress the ubiquitous problem of imperfect model assump-
tions. On this point it should be emphasized that compari-
sons of results using models of varying degrees of
mechanistic sophistication and varying numbers of param-
eters is important. As the quality of the data improves, the
sophistication of the models may need to be increased. This
could involve more sophisticated assumptions and/or an in-
creased number of parameters. For the parotid saliva analy-
sis, a wide range of models ~more than 20! were examined,
and it was found that, with the data at hand, at least three
different two-parameter models described the data to very
similar accuracies.55,57 It is desirable that a range of fitted
models be reported, to give readers and other investigators a
clearer idea of what sort of models describe the data well
and, almost equally important, what sort of models fit the
data poorly. Useful metrics for model selection include met-
rics based only on the relative ranking of treatment plans,
such as Spearman’s rank correlation coefficient58 ~in cases
where the severity of the outcome is graded!, and the ‘‘ad-
justed mean square error’’ ~AMSE!, which attempts to esti-
mate the prediction error the model will have for new
datasets. AMSE is equal to ~residual square error!/(n22p),
where n is the number of data points and p is the number of
model parameters. The factor 1/(n22p) is a more severe
penalty for an increased number of model parameters than
the unbiased variance factor 1/(n2p). Other methods for
estimating model prediction error can be found in Ref. 54.
Levegrun et al. have used receiver operating characteristic
curves to judge the goodness of various predictive models.51
An important related, but unaddressed, problem is that the
models can naively be applied to any dose distribution,
whereas the data typically have been ~and will probably be!
derived using dose distributions that are clustered ~similar! in
terms of their geometrical characteristics. Inevitably, the
models will be applied in cases where the dose distributions
are very different from those that comprised the clinical
dataset upon which the model and parameter selection was
based. This might be termed the ‘‘terra incognito’’ problem.
We will need new statistical methods to recognize when the
plan evaluation is highly extrapolative as opposed to more
safely interpolative. In general, it appears possible that we
could engineer much stronger links between the original
clinical data and the plan ranking process, and this is an
attractive area of potential investigation.
Although tolerance models ~i.e., NTCP! have typically
been used to analyze complication data, some types of data,
such as saliva reduction due to parotid gland irradiation, are
probably best described by bioeffect models that describe
how some biological end point varies with dose–volume
changes.55–57 For bioeffect models, data at doses much less
than the typical tolerance doses can be used to understand
the trend toward unacceptable toxicity. Any measurable
quantity that continuously changes with dose and which is
2117 Deasy et al.: Methodological issues in radiation dose-volume outcome analyses 2117thought to be related to an important outcome might be an
interesting candidate for investigation. Functional imaging
may also be used to determine other useful bioeffect metrics
~such as lung perfusion59!. Last, we emphasize that if a rel-
evant bioeffect marker can be developed for a given out-
come, the statistical precision of fitted parameters, and the
sophistication of the models that can be investigated, im-
prove dramatically. This is due to the fact that all patients
yield informative data, not only on the presence of radiation
damage, but also on the magnitude of the damage.
Time and fractionation effects will continue to play an
important role. One underinvestigated yet potentially impor-
tant effect is cellular repair on a time scale of minutes rather
than hours. DNA double-strand break repair cannot be de-
scribed as the result of a single exponential time constant.60
Cannay and Millar conclude that there are roughly two com-
ponents to cellular repair: one fast ~with a half-time of the
order of 10–15 min! and one slower ~with a half-time the
order of several hours!.61 They estimate that if such nonmo-
noexponential repaire kinetics occur in human tissue systems
the probability of acute complications could be affected by
approximately 25%. Recent calculations show that the differ-
ence in biologically effective dose for late-responding nor-
mal tissues between delivering 2 Gy to any tissue volume in
1 min versus spreading out or pulsing delivery to the same
tissue volume over, say, 20 min could be on the order of
5%–10%.62 Clearly dose-rate effects are an open issue for
IMRT and stereotactic treatments whose session delivery
times vary significantly. Potential dose-rate effects are yet
another reason why IMRT delivery efficiency should be im-
proved so that delivery times are consistent with non-IMRT
delivery durations.
The evolution of dose–volume-outcome models toward
becoming useful clinical tools would be aided greatly if re-
searchers were to archive, in a publicly available fashion, all
of the relevant treatment planning and outcome data upon
which publications are based. This would allow workers to
compare new results ~datasets and models! with old, and
would thereby be highly useful for further improving the
scientific basis for dosimetric treatment planning decisions.
V. THE EFFECT OF PATIENTÕORGAN POSITIONING
VARIATION ON TREATMENT AND PLANNING
EVALUATION
Di Yan
Treatment variation in positioning of the patient/organ
with respect to the treatment beams causes a temporal dose
variation in critical normal tissues adjacent to the treatment
target. Consequently, this temporal variation induces uncer-
tainties in understanding the normal tissue dose response,
thereby preventing reliable treatment evaluation and optimi-
zation. Numerous studies have been performed in the last
decade to evaluate the potential effect of the temporal dose
variation. However, the results are quite inconclusive and
controversial. Besides patient-related factors, disagreements
have been caused by the models and assumptions applied inMedical Physics, Vol. 29, No. 9, September 2002each study. The following discussion outlines the quantifica-
tion and evaluation models for studying the temporal dose
variation, and their potential limitations.
Quantification: The geometric configuration of an organ
of interest in pretreatment planning is determined by using
positions of its subvolumes at the time of treatment simula-
tion. Internal organ motion/deformation and patient setup er-
ror during the process of radiation delivery result in the dis-
placements of these subvolumes with respect to their
planning positions. Therefore, treatment variation in posi-
tioning of any organ can be quantified using the displace-
ments of its subvolumes from the planning positions to the
actual treatment positions.
The displacements can be determined based on the nature
of the geometric variation in question, using a rigid body
motion model and/or a nonrigid body motion model. Rigid
body motion has a distance conserving property for any pair
of subvolumes, and therefore implicitly assumes that patient
organs maintain their shape and size during the treatment
course. The rigid body motion model has been applied to
measure the relative position of patient rigid bony structure
with respect to the radiation beam in computing patient setup
error.63 In this case, a linear transformation, determined us-
ing the displacement of a few fiducial points in the bony
structure, can be used to represent the entire structure’s mo-
tion. However, the assumption of rigid body motion is lim-
iting and unnatural for a human soft organ.
Using nonrigid body motion to study patient soft organ
motion/deformation is a more appropriate model and has re-
ceived more attention recently.64 –66 Unlike the rigid body
motion model, the nonrigid body motion model groups all
subvolumes in a deforming organ under a biomechanical
structure with tissue elasticity and/or compressibility. Each
subvolume displacement is then calculated by applying the
finite element method.
Characterization: In the radiation treatment process, the
patient organ geometry as manifested on treatment simula-
tion image is used in pretreatment planning as the reference
for treatment delivery. Any deviation between the actual
treatment positions of an organ subvolume and its reference
position represents an unfavorable displacement caused by
either internal organ motion/deformation or patient setup er-
ror at the treatment. For a given patient, the difference be-
tween the mean of treatment positions of a subvolume and its
simulation position has been used to quantify the systematic
displacement m of the subvolume position. Similarly, each
treatment position subtracted by the mean has been defined
as the random displacement of the subvolume. The system-
atic displacement and the standard deviation s of the random
displacement have been commonly used to characterize a
patient-specific geometric variation, such as daily setup error
of the individual.67
General organ displacement with multiple patients’ data
can be characterized using a preselected fiducial point com-
mon to each patient. The fiducial point has typically been
selected to represent either the average motion or the maxi-
mum motion of the organ in a given direction. When organ
motion data for a large number of patients is pooled, one can
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nitude of the standard deviation of fiducial point displace-
ment. The sequence of position displacements during the
treatment for the patients in a given group can be mathemati-
cally modeled as a random process, in which each patient has
different systematic displacement based on his or her simu-
lation position, and a similar standard deviation of the ran-
dom displacement. With this classification, one can observe
and identify an important property for intertreatment geomet-
ric variation: the systematic displacement among patients in
a specific group has a probability distribution similar to the
distribution of the random displacements, if similar proce-
dures for patient setup and organ location are applied for
both simulation and treatment. This property was observed
and discussed by Bijhold in the early 1990s67 for a study of
patient setup error, and it is also true for the general displace-
ment of an organ subvolume during the treatment course.68
Tables I and II show a specific example of intertreatment
prostatic motion obtained from a previous study.69 This prop-
erty also indicates that a group of patients who have the
broadest distribution of the random displacement in their
daily setup position and/or internal organ location will also
have the broadest distribution of their systematic displace-
ment. Therefore, treatment planning evaluation and generic
CTV-to-PTV margin design should consider this feature.
Dosimetric effect: Dose deviation in organs of interest
caused by patient/organ geometric variation can be decom-
posed into two parts and considered independently.69 The
first part represents the deviation in the absorbed dose at a
spatial point due to patient configuration ~e.g., skin surface!
and/or internal tissue density distribution changes ~e.g., den-
sity of the lung and the other hollow organs!. These changes
result in a discrepancy between the dose calculated at treat-
ment planning and the dose actually delivered at the same
spatial point. This effect could be significant for a hollow
organ or organ adjacent to bone, and can be better deter-
mined by reconstructing dose based on an on-line treatment
TABLE I. Treatment setup error ~mm! for 30 prostate patients.
Group 1 Group 2 All
~mm! Syst
s~m!
Rand
s~j!
Syst
s~m!
Rand
s~j!
Syst
s~m!
Rand
s~j!
AP 2.0 1.5 4.0 3.0 2.9 2.2
SI 1.6 1.2 2.2 2.2 1.9 1.8
RL 1.5 1.5 2.4 2.8 1.8 2.2
TABLE II. Target (prostate1sv) COM motion ~mm! for 30 prostate patients.
COM5center of mass.
Group 1 Group 2 All
~mm! Syst
s~m!
Rand
s~j!
Syst
s~m!
Rand
s~j!
Syst
s~m!
Rand
s~j!
AP 3.3 1.9 4.6 3.3 3.6 2.6
SI 2.3 1.7 3.3 2.4 2.5 2.0
RL NA NA NA NA NA NAMedical Physics, Vol. 29, No. 9, September 2002CT image. Here, it is assumed that the variation of machine’s
output and errors of dose calculation are minimal, and neg-
ligible. The second part represents the dose deviation due to
the actual position displacement of the subvolume with re-
spect to the anatomical landmarks, which can be determined
using the knowledge of subvolume displacement calculated
by considering organ motion/deformation and setup error. In
the following discussion, we will focus on the dose deviation
due to subvolume displacement alone.
The cumulative dose deviation in a subvolume can be
calculated by directly convolving the dose distribution with
the distribution of organ subvolume displacement,70 or
approximated69 as
DD’mTn¯ d@x0 ,x01m#1sT" ~n21 !2
 ]
2d
]x2
~x01m!"s, ~5!
where x0 represents the subvolume position at the treatment
simulation, m and s are the systematic displacement and the
standard deviation of the random displacement, n is the num-
ber of treatment fractions, and ¯ d@x0 ,x01m# and
(]2d/]x2)(x01m) are the mean dose gradient in the interval
@x0 ,x01m# and curvature of the dose distribution at the
point x01m. Using this relation, the cumulative dose devia-
tion can be evaluated approximately by using the systematic
displacement and the standard deviation of the random dis-
placement alone, without considering the specific distribu-
tion of the displacement. Therefore, we can conclude the
following: the cumulative dose deviation for a organ subvol-
ume is more sensitive to the shape of the dose profile (rela-
tive to the dose gradient and curvature), and less sensitive to
the shape of the subvolume displacement distributions, as
long as those distributions have equal systematic displace-
ment and the same standard deviation of the random dis-
placement.
The cumulative dose deviation caused by the geometric
variation, or the resulting deviation of the normal tissue com-
plication probability ~NTCP!, has been commonly applied to
evaluate normal tissue dose responses and treatment plans.
However, this evaluation potentially masks the effect of the
random displacement, particularly for critical normal organs
adjacent to the treatment volume. This is because the adja-
cent normal organs are commonly located at the linear por-
tion of the dose penumbra region, where the dose distribu-
tion curvature is small, but the dose gradient has its
maximum. Figure 6 indicates the frequency distribution of
fraction dose deviations, as well as the corresponding cumu-
lative dose deviations, to two subvolumes, which are located
in the treatment planning on the 40% and 90% isodose sur-
face, respectively. The fractional dose deviations were calcu-
lated by simulating the subvolume displacement as a Gauss-
ian distribution with zero mean, representing no systematic
displacement, and 5 nm standard deviation, characterizing
the random displacement. The result demonstrates that the
spectrum of fraction dose deviations is broad, with more than
2119 Deasy et al.: Methodological issues in radiation dose-volume outcome analyses 2119100% difference between the maximum and minimum val-
ues, however the corresponding cumulative dose deviation is
less than 10%. Furthermore, a similar or even identical cu-
mulative dose deviation can arise from totally different spec-
trums of fraction dose deviations. This implies that using the
cumulative dose deviation alone to perform treatment evalu-
ation ignores the effect of fraction dose deviation, and could
misinterpret the treatment dose response for organs of inter-
est, particularly for critical normal organs. Moreover, this
issue becomes even more problematic when a treatment has
a small targeting margin and sharp dose gradient.
Radiobiological effect: Effect of the fraction dose devia-
tion in an organ of interest can be evaluated using the bio-
logical effective dose ~BED!,71,72 which is the equivalent to-
tal dose if given in infinitely small fractions. The deviation of
BED for an organ subvolume calculated using the planned
dose and delivered dose can be denoted69 as
DBED5S 11 2dpa/b D DD1 1a/b (t51
n
@Ddt#2, ~6!
where dp is the dose in the subvolume initially calculated at
treatment planning, therefore the corresponding BED at the
treatment planning is BED5ndp(11dp /a/b), DD is the
cumulative dose deviation, and Ddt is the fraction dose de-
viation to the subvolume between the actual delivery at the
treatment t and the planning calculation. Therefore, the ra-
diobiological dose deviation DBED is proportional to both
the cumulative dose deviation and the square of the fraction
dose deviation. Furthermore, the BED deviation is more pro-
nounced for late reacting normal tissues, due to the smaller
a/b values. Therefore, significant deviation on the biological
effective dose could be expected in a critical normal struc-
ture, even if the cumulative dose deviation in this structure is
negligible. Patients with similar geometric variation charac-
teristics can experience different BEDs, and the differences
are very sensitive to the dose gradient and the total number
of treatment fractions.
Figure 7 shows the distribution of BED deviations among
patients to a subvolume located at the 80% isodose line dur-
ing the treatment planning. The value in Fig. 7 was calcu-
lated for three groups of patients with the subvolume dis-
FIG. 6. Cumulative dose deviation DD and the distribution of fraction dose
deviation Ddt in a subvolume. Both deviations are normalized to the corre-
sponding planned dose.Medical Physics, Vol. 29, No. 9, September 2002placement ~in one dimension! of each group: (m ,s)
5(4,5), ~0, 5!, or ~24, 5! mm, respectively. The frequency
of patients who experience different BEDs was plotted by
normalizing their DBEDs to the planned value, with the pre-
scribed fraction dose 2 Gy for total treatment fractions n
535. The results demonstrate that a broad spectrum of bio-
logical dose response variation can occur in clinical treat-
ment, even if a given group of patients have similar geomet-
ric variation characteristics.
VI. EVIDENCE OF VOLUME EFFECTS FOR
RECTAL BLEEDING
Andrew Jackson
Treatment planning for the external beam radiotherapy of
cancers rests on a few simple principles. One of the most
important is that tolerance doses for normal tissues depend
on the exposed volumes of the involved organs ~i.e., there
are volume effects!. This assumption provides the basis for
the many Phase I dose escalation trials currently in progress,
which use the information provided by CT scans and 3-D
dose distributions to design treatments that minimize normal
organ exposure while raising the dose to the target. The ex-
istence of volume effects is widely held to be true, but for
clinical endpoints the supporting evidence is often of poor
quality and sparse. There are clear reasons for this; some
historical and some intrinsic to the nature of complications.
A specific example will illustrate these problems: evi-
dence for volume effects in rectal bleeding after radio-
therapy. When severe, rectal bleeding can be a dose limiting
late complication of external beam radiotherapy for prostate
cancer.
Estimates of partial volume tolerance doses were com-
piled by Emami et al.73 and gathered mostly from experience
of complications that occurred before the era of 3-D treat-
ment planning, when little or no quantitative data was avail-
able on the exposed volumes of involved organs. At that
time, Emami et al. stated that there was no volume effect for
severe late effects in the rectum, while admitting that pub-
lished articles contained little or no volume information. Ma-
FIG. 7. Distribution of BED deviations in a subvolume for three groups of
patients. The displacement in each group of patients has m and s to be ~4
mm, 5 mm! ~dot-n–dashed curve!, ~0 mm, 5 mm! ~dashed curve! or ~24
mm, 5 mm! ~solid curve!, respectively.
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cancer to various doses in the range 50–65 Gy, saw a corre-
lation between bowel complications and inclusion of the
whole pelvis in the irradiated volume. Dearnaley et al.75 con-
ducted a randomized clinical trial of nonconformal and con-
formal radiotherapy for prostate cancer and demonstrated a
decrease in late rectal bleeding ~RTOG grade 2 or higher!
from 15% to 5%.
Dose–volume data from 3-D conformal dose escalation
studies have also indicated that volume effects for rectal
bleeding exist. Benk et al.76 reported data from Dose Volume
Histograms ~DVHs! of 41 patients treated by photon whole
pelvis and proton boost fields to 75.6 Cobalt Gy Equivalent
~CGE!, with the rectum localized using a probe. Fourteen
patients developed rectal bleeding, ~6 grade 1, and 8 grade 2
using the RTOG classification77!. A significantly higher inci-
dence of bleeding was observed among those patients with
>40% of the anterior rectal wall receiving 75 CGE. Subse-
quent analysis of the same data by Hartford et al.78 showed
that dose–volume cutoffs at lower doses ~down to >70% of
the anterior wall receiving 60 Gy! also produced significant
correlation with bleeding, as did a model of NTCP. Schulth-
eiss et al.79 reported high actuarial rates of grade 2 and 3 GI
morbidity following prostate treatment using a four-field
technique, showing a strong dose response. For patients
treated to 73–76 Gy to the isocenter, a significant reduction
in morbidity was observed in those patients for whom rectal
shielding was increased for the last 10 Gy of treatment. It
was not clear if this was due to a volume effect, or to the
decrease in dose to the rectal wall, since the DVHs were not
analyzed. Boersma et al.80 studied DVHs from 130 patients
treated for prostate cancer to isocenter doses between 70–78
Gy in 2 Gy fractions with three-field 3DCRT. Pelvic nodes
were treated to 64% of the prescription dose at a lower dose
per fraction using a simultaneous boost technique delivered
with partial transmission shielding, and doses above 70 Gy
were delivered with additional rectal shielding. Grade 2 or
higher rectal bleeding ~RTOG! was observed in 18 patients,
four of whom required one or more laser treatments and
blood transfusions. No significant correlation with dose–
volume parameters was seen for grade 2 rectal bleeding.
However, for the four cases of severe rectal bleeding, a sig-
nificant correlation with volume receiving doses greater than
65 Gy was seen. Recently, Skwarchuk et al.81 and Jackson
et al.82 have studied patients treated prone with a six-field
technique to 75.6 Gy at Memorial Sloan–Kettering Cancer
Center. These studies included 36 patients with grade 2 rectal
bleeding by 30 months and a random sample of 83 out of
192 eligible patients without grade 2 bleeding at 30 months.
The percent volumes of rectal wall exposed to 47 and 77 Gy
were both found to be significantly correlated with grade 2
rectal bleeding. Additional analysis of this data indicates that
a functional reserve of tissue receiving less than 40–50 Gy
may be important in preventing rectal bleeding.83 A recent
article by Fenwick,84 which found a dependence of rectal
bleeding on the area of rectal wall receiving >57 Gy lends
support to the hypothesis that the extent of exposure to rela-
tively low doses may play a role in causing rectal bleeding.Medical Physics, Vol. 29, No. 9, September 2002Properly conservative treatment practice naturally limits
the number of serious complications ~‘‘responders’’! that
arise, severely limiting the statistical power of studies from
single institutions. While studies without responders may
help to define regions of safe treatment, only studies with
responders can locate the boundary of safe treatment. In all
the recent reports, the raw numbers of severe cases of rectal
bleeding reported were small: Benk/Hartford et al.: 1 case of
grade 3 bleeding; Boersma et al.: 4 cases requiring laser
surgery/transfusion; Schultheiss et al.: 15 cases of grade 3
morbidity. Studying the volume effect in such small numbers
of patients all treated with a similar technique is very diffi-
cult. Studying grade 2 complications has the advantage of
better statistics. However, the grade 2 endpoint is not dose
limiting, and its diagnosis is more subjective. Some justifi-
cation for studying this end point comes from the study of
Schultheiss et al., which showed that the rate of grade 3 GI
complications also rose when the grade 2 rate rose above
20%.
Data from single institutions, often involving single treat-
ment techniques, may not provide an adequate range of dose
volume combinations from which to determine volume ef-
fects. For example, while Schultheiss et al. found that treat-
ment of the whole pelvis to 45 Gy was not significantly
associated with increased GI morbidity ~in contrast to the
results of Skwarchuk et al. and Jackson et al.!, the studies of
Benk et al., Hartford et al., and Boersma et al. could shed no
light on this issue, since all patients received irradiation with
large pelvic fields to 44–50 Gy.
Other ~perhaps intractable! problems arise when compar-
ing results from different institutions. For example, organ
motion may be expected to change the dose delivered from
the planned dose, but the extent and location of these effects
may depend upon institution-specific factors such as patient
setup ~e.g., supine or prone! and treatment technique ~e.g.,
patients in the studies of Benk et al. and Hartford et al. were
treated with a perineal proton boost field with the rectal wall
fixed with a probe!. Finally, and importantly, endpoints used
to study the outcome are difficult to define ~especially for
low-grade complications! and may differ not only from in-
stitution to institution, but also from physician to physician.
Despite the limitations imposed by poor statistics, treat-
ment technique, organ motion, and the difficulties inherent in
comparing results from different institutions, evidence is
emerging, from 3-D conformal dose-escalation trials, that
demonstrates the existence of volume effects in late rectal
bleeding. Continued accumulation and careful analysis of
this data is the only way we might hope to quantify these
important limitations on external beam radiotherapy for pros-
tate cancer.
VII. USING DOSE–VOLUME MODELS TO DESIGN
CLINICAL TRIALS: NORMAL TISSUE-BASED
DOSE ESCALATION IN LIVER AND LUNG
Randall K. Ten Haken
Liver and lung belong to a group of normal tissues gen-
erally believed to ~a! exhibit a ‘‘volume effect,’’ ~b! sustain
2121 Deasy et al.: Methodological issues in radiation dose-volume outcome analyses 2121damage in a ‘‘parallel’’ versus ‘‘serial’’ fashion, and ~c! be
subject to a ‘‘functional reserve’’ below which damage may
not cause injury and above which injury results. This makes
their study attractive for NTCP modeling. Liver studies rep-
resent perhaps the best hope for modeling. The volume and
dose can be estimated fairly well, local damage may exhibit
a response to dose, and the relationship of cumulative local
damage to organ injury may also be indicated. Due in part to
a desire for aggressive treatment, the consequences of lung
irradiation have received more attention. However, modeling
will remain challenging due to many issues associated with
the assessment of lung complication data. Issues include the
definition of an end point ~pneumonitis, fibrosis, etc.!, con-
founding factors such as preexisting disease and chemo-
therapy, modeling lung function ~nonuniform distribution of
FSUs, regional differences in FSU radiosensitivities and
function!, and compensatory effects. Functional imaging85–88
can help in the assessment of some of these effects. How-
ever, dose distributions in both liver and lung are suspect due
to organ motion due to patient breathing.89 Despite these
concerns, general approaches to systematically gather patient
data are needed and are starting to emerge. Thus, treatment
planning and better understanding of normal tissue compli-
cations remain as challenging issues for those involved in the
treatment of lung and liver cancer,90–100 to list a few.
Variations on one general approach toward implementing
NTCP models for liver and lung have been adopted at sev-
eral treatment centers.90,94,98,101,102 First, one treats patients
and collects 3-D dose–volume data, together with the assess-
ments of patient outcome. Next, a retrospective analysis can
be performed to estimate parameters of a descriptive NTCP
model.103,104 Finally, a prospective ‘‘normal tissue dose esca-
lation’’ trial may be started, escalating groups of patients
from nominal iso-NTCP levels according to common levels
of risk. This contrasts with standard dose trials that deliver a
target dose without regard to the volume of normal tissue. As
a consequence, these types of trials accommodate the intro-
duction of new technologies that may produce more confor-
mal dose distributions. Although the target volume dose dis-
tribution may change, corresponding changes in the
prescription dose ensure that the same normal tissue risk lev-
els are maintained. Thus, the data from a new patient, treated
with an advanced technology, is guided by the same iso-
NTCP level as the previous patient treated with the older
technology. As more outcome data are acquired, it should
then be possible to continue to refine model parameters or
use the data for input to test other models.
Recent trials in the treatment of intrahepatic tumors help
to illustrate this approach. Substantial retrospective data sug-
gested that parts of the liver could safely receive far higher
doses than traditionally delivered. In 1987 a series of studies
using 3-D conformal therapy were begun based on two fun-
damental concepts. First, the ability existed to significantly
reduce the dose to the normal liver.105 Second, conformal
treatment planning permitted quantification of the fraction of
normal liver irradiated that could be conveniently expressed
for input in a NTCP model. The first trial used a simple
scheme based on the volume of a normal liver receivingMedical Physics, Vol. 29, No. 9, September 2002.50% of the prescription dose.106 For both colorectal can-
cers metastatic to the liver and primary hepatobiliary can-
cers, far higher tumor response rates were observed than had
previously been possible using radiation.107 Retrospective
analysis of those data allowed the refinement of parameters
of the Lyman model108 to describe the probability of causing
radiation-induced liver disease, based on both the radiation
dose and the liver volume irradiated.109 Subsequently, a new
prospective trial was initiated in an attempt to safely escalate
the dose of radiation for patients with intrahepatic cancer.
The trial uses a protocol98 in which each patient receives the
maximum possible dose while being subjected to a preset
risk of radiation-induced liver disease ~RILD! or ‘‘radiation
hepatitis’’ based on a normal tissue complication probability
~NTCP! model.108,110 The goal of planning is to maximize
the dose to the target while both minimizing the effective
volume Veff for the liver and respecting other dose-limiting
organs. This is made possible through the realization102 that
the computation of Veff is independent of dose ‘‘units.’’ That
is, the value of Veff depends only on the shape of the DVH
and the relative value of Dref. Therefore, a value of Veff may
be computed for each patient from a relative isodose distri-
bution ~%! before a physical dose ~Gy! ~based on an iso-
NTCP level! is prescribed. Early results indicate91,92,98 the
dose delivered using this approach is significantly higher
than the dose that would have been delivered by the previous
protocol, and data for use in NTCP analysis continues to be
accrued. These results suggest that a NTCP model based on
patient data ~rather than literature estimates! can be used pro-
spectively to safely deliver far higher doses of radiation with
a more consistent risk of complication than would have pre-
viously been considered possible for patients with intrahe-
patic cancer. However, clearly, multi-institutional studies will
be required to obtain significant numbers of events to permit
a good parameterization of model parameters.
A major potential impediment to effectively modeling
normal tissue dose-volume relationships in the abdomen and
pelvis is including the effects of patient breathing in the re-
sulting dose distributions. Treatment planning CT scans
~even if done with a breath-hold! illustrate the shape and
position of thoracic and abdominal structures at one point in
time and thus may poorly predict the actual patient status for
dose calculations unless similar breath-hold procedures are
used at treatment.111,112 The dosimetric corrections intro-
duced by geometric changes can be as large as the uncertain-
ties often associated with the dose calculation density correc-
tion algorithms.113,114 Current treatment plans include a
margin for ventilation, typically based on the fluoroscopic
observation of the tumor shadow and/or diaphragm under
ventilation at simulation. While this may ensure tumor vol-
ume coverage, it leads to larger than necessary treatment
volumes and can produce misleading NTCP estimates. That
is, even given that ~when done properly! standard practice
~PTV formation! could help assure that CTVs would indeed
receive their desired doses, traditional initial dose distribu-
tion calculations would not include the effects of uncertain-
ties from daily setup variations and organ motion. Thus, they
would not represent dose distributions actually received by
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indicate that clinically meaningful ~several fraction! differ-
ences in the prescribed dose could result if dose distributions
that include the effects of organ motion were used in place of
the original static treatment plans.115,116 Clearly, further stud-
ies of the impact of patient-related geometric variations on
normal tissue dose distributions are called for.
VIII. THE EFFECT ON PLAN EVALUATION OF
UNCERTAINTY IN TOLERANCE LIMITS
Mark Langer
The levels of radiation dose that can be tolerated by dif-
ferent tissues are not precisely known, and this uncertainty
makes it difficult to compare treatment plans. Comparisons
become uncertain when a small change in a tolerance limit
produces a large change in the dose delivered to the tumor.
Not all tolerance limits have the same effect on tumor dose.
The selection of treatment plans can be improved by focus-
ing efforts to reduce tolerance uncertainty on those limits for
which small errors cause the greatest shortfalls in tumor
dose. Modern methods for plan construction allow the sensi-
tivities of tumor dose to errors in tolerance limits to be dis-
covered.
A wide range of tolerance limits for different organs can
be found in the literature or in protocol rules. Dose limits for
the spinal cord found among protocols that outline the radio-
therapy to be used for a single condition—small cell lung
cancer treated with coincident platinum-based chemotherapy
range from 44 Gy in 22 fractions to 50 Gy in 25 fractions, a
variation of 14%.117,118 The volume fraction of the heart that
protocols require to be protected is nearly always 50%, but
the dose limit on this protected fraction can range from
30–50 Gy. Both the threshold dose and the protected volume
of the lung to be maintained in thoracic radiation are uncer-
tain. A cutoff of 30 Gy for up to 70% of the total lung is
specified in a small cell protocol using coincident chemo-
therapy, while a dose cutoff of 20 Gy for a stratified set of
lung volumes has been adopted by the RTOG for their tumor
dose escalation protocol 93-11.117,119 In the literature, the
threshold dose level used to relate pulmonary damage to the
lung volume irradiated to beyond that level has been taken to
be either 30 or 20 Gy.120,121 Some studies do not use dose–
volume constraints, but rather continuous response models,
as discussed above. Small changes in a tolerance limit can
produce large effects on the dose that can be delivered to the
tumor, but the effect of uncertainty on tumor dose need not
be the same from one limit to the next. A study evaluating
the benefit of a computer controlled technique for treating
lung cancer found that the gain over a conventional method
was very sensitive to the volume of contralateral lung per-
mitted to receive more than a threshold dose of 20 Gy. If the
lung volume allowed more than 20 Gy was restricted to 27%,
the gain by substituting a computer controlled technique for
conventional therapy was 7 Gy, but further tightening the
volume limit to 25% reduced the gain to only 1 Gy.122 A
larger study found that the minimum target dose that could
be achieved with conventional therapy could be increased inMedical Physics, Vol. 29, No. 9, September 2002two of six cases by more than 9% to reach a level greater
than 80 Gy by expanding by 2%–3% the volume of the
contralateral lung allowed to receive a threshold dose of 20
Gy.123 While gains in tumor dose for lung cancer treatment
may be very sensitive to the limit on the lung volume that is
allowed to receive greater than some threshold dose, the ex-
act setting of the threshold dose level may be less important.
It has been suggested that the volume of lung receiving .20
Gy and the volume of lung receiving .30 Gy may be tightly
correlated parameters, at least when traditional plans are
used.124 It may be that the minimum tumor dose is more
sensitive to small changes to a volume limit than to a dose
limit. In this case, a phase I study will yield the greatest gain
in target dose for a given reduction in the uncertainty of a
tolerance limit if it is designed to reduce the error in the
maximum volume allowed a given dose and not the maxi-
mum dose allowed in a given volume.
The sensitivity of tumor dose to tolerance uncertainty can
readily be discovered using an optimization package for
beam weighting that can quickly construct a treatment plan
given rules on the volume distribution of dose in critical
structures, including target and normal tissues. In a series of
lung cancer patients whose boosts were planned using a
computer controlled technique, small changes in a limit on
dose inhomogeneity within the target produced large changes
in the minimum tumor dose that could be delivered. A mini-
mum tumor dose of .80 Gy could be delivered in all six
cases examined when an inhomogeneity limit of 20% was
accepted, but the minimum tumor dose fell to the range
44–64 Gy when the limit was tightened to 13%–17%.125
An example of the differences that can be seen in the
sensitivity of tumor dose to various tissue limits is shown in
Fig. 8 for a hypothetical model. The figure depicts the high-
est value for the minimum tumor dose that can be obtained
under different combinations of partial volume limits for two
tissues. For tissue 1, a reduction of 5%, from to 75% to 70%,
in the volume held to a dose <20 Gy allows a large increase
FIG. 8. Minimum tumor dose possible for different combinations of dose
volume constraints on two tissues.
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about 16 Gy. On the other hand, changes in the volume of
tissue 2 that must be held to a dose <30 Gy, within the range
of 65%–85%, barely affect the minimum tumor dose that
can be obtained. If similar findings were seen in clinical
series, then a planned phase I dose escalation trial should be
designed to reduce the uncertainty in the tolerance limit for
tissue 1 rather than for tissue 2 if the aim is to allow the
greatest possible increase in tumor dose for a given reduction
in uncertainty. In clinical applications, similar behavior
might be observed in the treatment of thoracic tumors, with
tissue 1 representing lung and tissue 2 representing heart.
When new treatment methods are applied, small relaxations
in the dose constraints that have been traditionally set may
be introduced. An example is the relaxation in inhomogene-
ity limits that has accompanied the use of intensity modu-
lated radiotherapy. The relaxations confound the ability to
assess the merits of the new techniques. The dose gains seen
might be the consequence of the relaxed dose constraints and
not the new technology per se.
The acute sensitivity of tumor dose to small changes in a
tolerance condition implies that any comparison of treatment
techniques should adhere to a rigid set of rules. Not uncom-
monly, one finds that a new treatment technique trades off a
small deterioration in the dose distribution in one structure
for a larger gain in another.126 Even if the deterioration pro-
duced in one structure is so small as to be felt to be clinically
unimportant, the newer technique cannot be said to be supe-
rior. Had the older technique been allowed the same small
relaxation of the dose distribution in the first structure, it
might have produced the same gain in the dose distribution
in the second. Relaxations as small as 2%–3% in the lung
volume receiving >20 Gy were found in one study to com-
pletely eliminate the gains attributed to conformal therapy
over standard techniques for treating lung cancer.123 Data
describing the sensitivity of the objective to changes in the
constraints over a wide range of values have been recently
reported for clinical cases in the abdomen and prostate.127,128
The sensitivity problem is not eliminated by the introduc-
tion of score functions that rate the dose distributions in dif-
ferent structures rather than demand that a set of constraints
be satisfied. The score functions themselves have errors
whose sizes are seldom estimated. Even if score functions
correctly order plans according to their probabilities of pro-
ducing reactions in different tissues, the overall ranking of
the plans by the probability of avoiding any tissue complica-
tion may still be wrong.129 There is a strong connection be-
tween maximizing an objective subject to constraints, and
maximizing a weighted function of the constraint terms and
the objective. When the feasible space is piecewise convex,
the solution to the first problem corresponds to a solving the
second problem for a particular set of weights.130 If there are
errors in the constraints, then there will also be errors in any
function that scores plans by weighting their deviations from
the constraints.
Treatment techniques are best compared by considering
the sensitivity of the delivered tumor dose to errors in the
specification of the constraints. If tumor control or normalMedical Physics, Vol. 29, No. 9, September 2002tissue complication probabilities are used to compare plans,
the error in their individual terms should be determined and
propagated to give an error in the overall score. Phase I
studies should be designed to reduce the error in the dose or
volume limit that would allow the largest increase in tumor
dose were its uncertainty made smaller. This determination is
necessarily a computer-based exercise given typical patient
datasets. The effect on tumor dose of relaxing a constraint
within its range of uncertainty should be made available to
physicians involved in the selection of treatment plans.
IX. SUMMARY
Widespread availability of 3-D treatment planning sys-
tems has facilitated the analysis of outcomes based on the
planned dose distributions. Although volume-effects are dif-
ficult to study due to understandably small clinical-event
rates, volume-effects based on fully 3-D dose distributions
have been observed for rectal, liver, and lung end points,
among other sites. From the work presented here it is clear
that much more clinical data directed toward evaluation of
3-D conformal and IMRT dose distributions is necessary.
Points of emphasis include the following.
~i! Dose–volume outcome models with a minimal number
of parameters, which can describe the observed data and rank
dose distributions, for both normal tissues and tumors, will
potentially play an important clinical role and deserve further
development.
~ii! Pooled-data analyses, which utilize data and modeling
techniques from different institutions could potentially im-
prove both the range of validity of dose–volume outcome
models and the accuracy of model parameters.
~iii! Analyses of the cumulative uncertainties in the appli-
cation of radiobiological outcome models to individual pa-
tients, and the presentation of such uncertainties to clinical
users, is desirable.
~iv! Patient motion effects, such as breathing motion, can
significantly change the response to radiation. However, in
some cases such motion can be measured and modeled, and
thereby included in outcome data analysis.
~v! Volume-effect models can be effectively used as a
basis for dose-escalation protocols, thereby leading to better
models and ultimately better protocols.
~vi! Uncertainties in volume-effect models and dose-
volume constraints used for optimized treatment planning
have important clinical consequences. In particular, research
should focus on those aspects of models or constraints that
are more likely to impact the ability to safely deliver tumori-
cidal doses.
In order to harvest the benefit of advances in dose deliv-
ery techniques, we require quantitative, individualized, pre-
treatment estimates of risks and benefits. The present situa-
tion brings to mind words of Fermi: ‘‘...we must be prepared
for a long hard pull... .’’ 131
ACKNOWLEDGMENTS
This workshop was partially supported by the National
Institutes of Health ~NIH!. Individual investigators were also
2124 Deasy et al.: Methodological issues in radiation dose-volume outcome analyses 2124supported by NIH grants: No. CA50628 and No. CA21239
~AN!, No. CA85181 ~JOD!, No. CA71785 ~DY!, No.
CA59827 ~RTH!, and No. 2PO1-CA-59017 ~AJ!.
a!Corresponding author and address for reprints: J. O. Deasy, Department of
Radiation Oncology, Box 8224, Washington University Medical School,
510 So. Kingshighway Blvd., St. Louis, Missouri 63110. Telephone: ~314!
362-1420; electronic mail: deasy@radonc.wustl.edu
1 E. J. Hall, in Radiobiology for the Radiologist, 4th ed. ~Lippincott, Phila-
delphia, PA, 1994!, p. 478.
2 H. D. Thames and J. H. Hendry, in Fractionation in Radiotherapy ~Taylor
& Francis, New York, 1987!, p. 297.
3 A. Niemierko, ‘‘Reporting and analyzing dose distributions: a concept of
equivalent uniform dose.’’ Med. Phys. 24, 103–110 ~1997!.
4 A. Terahara, A. Niemierko, M. Goitein, D. Finkelstein, E. Hug, N. Lieb-
sch, D. O’Farrell, S. Lyons, and J. Munzenrider, ‘‘Analysis of the rela-
tionship between tumor dose inhomogeneity and local control in patients
with skull base chordoma,’’ Int. J. Radiat. Oncol., Biol., Phys. 45, 351–
358 ~1999!.
5 Q. Wu, R. Mohan, and A. Niemierko, ‘‘IMRT optimization based on the
generalized Equivalent Uniform Dose ~EUD!,’’ in ICCR 13, 2000,
Heidelberg, Germany.
6 H. R. Withers, J. M. Taylor, and B. Maciejewski, ‘‘Treatment volume and
tissue tolerance,’’ Int. J. Radiat. Oncol., Biol., Phys. 14, 751–759 ~1988!.
7 A. Niemierko and M. Goitein, ‘‘Modeling of normal tissue response to
radiation: the critical volume model,’’ Int. J. Radiat. Oncol., Biol., Phys.
25, 135–145 ~1993!.
8 A. Niemierko, ‘‘A generalized concept of Equivalent Uniform Dose,’’
Med. Phys. 26, 1100 ~1999!.
9 G. J. Kutcher, C. Burman, L. Brewster, M. Goitein, and R. Mohan, ‘‘His-
togram reduction method for calculating complication probabilities for
three-dimensional treatment planning evaluations,’’ Int. J. Radiat. Oncol.,
Biol., Phys. 21, 137–146 ~1991!.
10 J. T. Lyman, ‘‘Complication probability as assessed from dose–volume
histograms,’’ Radiat. Res., Suppl. 8, S13–S19 ~1985!.
11 D. E. Herbert, ‘‘Quality assessment and improvement of dose-response
models: some effects of study weaknesses on study findings. C’est mag-
nifique?’’ A Report of Task Group 1 of the AAPM Biological Effects
Committee ~Medical Physics Publishing, Madison, WI, 1993!, AAPM
Report No. 43.
12 A. Niemierko, ‘‘A unified model of tissue response to radiation,’’ Med.
Phys. 26, 1100 ~1999!.
13 K. S. C. Chao, J. O. Deasy, J. Markman, J. Haynie, C. A. Perez, J. A.
Purdy, and D. A. Low, ‘‘A prospective study of salivary function sparing
in patients with head and neck cancers receiving intensity-modulated or
three-dimensional radiation therapy: initial results,’’ Int. J. Radiat. Oncol.,
Biol., Phys. 49, 907–916 ~2001!.
14 G. E. P. Box, ‘‘Robustness in the strategy of scientific model building,’’ in
Robustness in Statistics, edited by R. L. Launer and G. N. Wilkinson
~Academic, New York, 1979!, pp. 201–236.
15 D. Herbert, ‘‘Quality assessment and improvement of dose response
models: Some effects of study weaknesses on study findings. C’est mag-
nifique?,’’ ‘‘Evaluation of Models for Dose-Response in Radiation On-
cology,’’ of the Biological Effects Committee, A Report of Task Group 1
~Medical Physics Publishing, Madison, WI, 1993!, AAPM Report No. 43.
16 L. Cohen, in Ref. 15, pp. i–iii.
17 J. F. Williamson, P. G. Goldschmidt, and T. Colton, ‘‘The quality of
medical literature: An analysis of validation assessments,’’ in Medical
Uses of Statistics, edited by J. C. Bailar, III and F. Mosteller, ~NEJM
Books. Waltham, MA, 1986!, pp. 370–391.
18 M. R. Chassin and R. W. Galvin, ‘‘The urgent need to improve health
care quality,’’ J. Am. Med. Assoc. 280, 1000–1004 ~1998!.
19 M. Hewett and J. Simone, in Ensuring Quality Cancer Care, Institute of
Medicine/National Research Council ~National Academic, Washington,
DC, 1999!.
20 J. E. Ware, ‘‘The status of health assessment 1994,’’ Annu. Rev. Public
Health 16, 327–354 ~1995!.
21 U.S. Congress Patient Outcome Research Act, 1989.
22 F. Mosteller ~personal communication, 1999!.
23 T. Chalmers, ‘‘Problems induced by meta-analysis,’’ Stat. Med. 10, 971–
980 ~1991!.
24 National Research Council, Combining Information. Statistical IssuesMedical Physics, Vol. 29, No. 9, September 2002and Opportunities for Research, Washington, DC, 1992.
25 T. Chalmers, ‘‘Meta-analysis in clinical medicine,’’ Trans. Am. Clin. Cli-
matol. Assoc. 99, 144–150 ~1987!.
26 L. Bero and D. Rennie, ‘‘The Cochrane collaboration. Preparing, main-
taining, and disseminating systematic reviews of the effects of health
care,’’ J. Am. Med. Assoc. 274, 1935–1938 ~1995!.
27 C. Naylor, ‘‘Gray zones of clinical practice: Some limits to evidence-
based medicine,’’ Lancet 345, 840–942 ~1995!.
28 S. B. Thacker and R. L. Berkelman, ‘‘Surveillance of medical technolo-
gies,’’ J. Public Health Policy 7, 363–377 ~1986!.
29 S. J. Senn, ‘‘Falsificationism and clinical trials,’’ Stat. Med. 10, 1679–
1692 ~1991!.
30 R. Brook, ‘‘Using scientific information to improve quality of health
care,’’ in Doing More Good Than Harm. The Evaluation of Health Care
Interventions, edited by K. Warren and F. Mosteller, Ann. N.Y. Acad. Sci.
703, 74–85 ~1993b!.
31 U.S. General Accounting Office, Cross Design Synthesis, GAO/OEND-
92-18. Washington, DC, 1992.
32 D. Herbert, ‘‘Response surfaces for binary events. An empirical basis for
radiation oncology,’’ in Proceedings of the 6th International Conference
on the Use of Computers in Radiation Therapy, edited by U. H. Rosenow
~Gottingen University Press, Gottingen, Federal Republic of Germany,
1978!, pp. 210–238.
33 D. Herbert, ‘‘An extreme value paradigm for the effect of size on target
volume on end results in radiation oncology,’’ Med. Phys. 10, 589–604
~1983!.
34 D. Herbert, ‘‘An empirical extreme value model of the volume effect in
radiation oncology,’’ in Optimization of Cancer Radiotherapy, Proceed-
ings of the 2nd International Conference on Dose, Time, and Fraction-
ation in Radiation Oncology, edited by B. Paliwal, D. Herbert, and C.
Orton ~American Institute of Physics, New York, NY, 1984!, pp. 381–
401.
35 G. E. P. Box, ‘‘The determination of optimum conditions,’’ in The Design
and Analysis of Industrial Experiments, edited by O. Davies ~Oliver and
Boyd, London, 1967!.
36 D. Herbert, ‘‘The bivariate probit model of uncomplicated control of
tumor: A heuristic exposition of the methodology,’’ Int. J. Radiat. Oncol.,
Biol., Phys. 39, 213–225 ~1997!.
37 R. M. Califf, D. B. Pryor, and J. C. Greenfield, ‘‘Beyond randomized
clinical trials: Applying clinical experience in the treatment of patients
with coronary artery disease,’’ Circulation 74, 1191–1194 ~1986!.
38 D. J. Hand, ‘‘Date mining: Statistics and more.’’ Am. Stat. 52, 112–118
~1998!.
39 L. Glass, ‘‘Nonlinear dynamics of physiological function and control,’’
Chaos 1, 247–250 ~1991!.
40 P. Anderson, ‘‘More is different,’’ Science 177, 393–396 ~1972!.
41 D. Herbert, ‘‘Modeling the effectiveness of radiation treatment,’’ in Bio-
medical Uses of Radiation, edited by W. R. Hendee ~Wiley-VCH, New
York, 1999!, pp. 1227–1288.
42 D. E. Herbert and D. J. Brenner, ‘‘The use of the linear quadratic model
in clinical radiation oncology can be defended on the basis of empirical
evidence and theoretical argument,’’ Med. Phys. 24, 1245–1248 ~1997!.
43 D. Herbert, ‘‘Overview of nonlinear dynamical systems and complexity
theory,’’ in Chaos and the Changing Nature of Science and Medicine: An
Introduction, edited by D. Herbert ~American Institute of Physics, New
York, NY 1996!, pp. 1–34.
44 L. Thomas, Late Night Thoughts on Listening to Mahler’s Ninth Sym-
phony ~Viking Press, New York, 1983!.
45 M. Goitein, A. Niemierko, and P. Okunieff, ‘‘The probability of control-
ling an inhomogeneously irradiated tumour: a strategem for improving
tumour control through partial tumour boosting,’’ presented at the 19th L
H Gray Conference: Quantitative Imaging in Oncology, Newcastle, 1997.
46 J. O. Deasy, ‘‘Tumor control probability models for nonuniform dose
distributions,’’ Proceedings of the 5th International Conference on Dose,
Time and Fractionation in Radiation Oncology: Volume and Kinetics in
Tumor Control and Normal Tissue Complications, Madison ~Medical
Physics Publishing, Madison, 1998!, pp. 65–85 ~also available from
http://castor.wustl.edu/;deasy!.
47 A. T. Tome and J. F. Fowler, ‘‘Selective boosting of tumor subvolumes,’’
Int. J. Radiat. Oncol., Biol., Phys. 48, 593–599 ~2000!.
48 J. O. Deasy, ‘‘Partial tumor boosts: even more attractive than theory
predicts,’’ Int. J. Radiat. Oncol., Biol., Phys. 51, 279–280 ~2001!.
49 A. E. Nahum and D. M. Tait, ‘‘Maximising local control by customising
2125 Deasy et al.: Methodological issues in radiation dose-volume outcome analyses 2125dose prescription for pelvic tumours,’’ in Advanced Radiation Therapy—
Tumor Response Monitoring and Treatment Planning, edited by A. Breit
~Springer-Verlag, Heidelberg, 1992!, pp. 425–431.
50 A. Terahara, A. Niemierko, M. Goitein, D. Finkelstein, E. Hug, N. Lieb-
sch, D. O’Farrell, S. Lyons, and J. Munzenrider, ‘‘Analysis of the rela-
tionship between tumor dose inhomogeneity and local control in patients
with skull base chordoma,’’ Int. J. Radiat. Oncol., Biol., Phys. 45, 351–
358 ~1999!.
51 S. Levegrun, A. Jackson, M. J. Zelefsky, E. S. Venkatraman, M. W.
Skwarchuk, W. Schlegel, Z. Fuks, S. A. Leibel, and C. C. Ling, ‘‘Analy-
sis of biopsy outcome after three-dimensional conformal radiation
therapy of prostate cancer using dose-distribution variables and tumor
control probability models,’’ Int. J. Radiat. Oncol., Biol., Phys. 47, 1245–
1260 ~2000!.
52 J. O. Deasy, ‘‘Inter-patient and Intra-tumor radiosensitivity heterogene-
ity,’’ in Ref. 46, pp. 363–381.
53 R. A. Britten, A. J. Evans, M. J. Allalunis-Turner, A. J. Franko, and R. G.
Pearcey, ‘‘Intratumoral heterogeneity as a confounding factor in clono-
genic assays for tumour radioresponsiveness,’’ Radiother. Oncol. 39,
145–153 ~1996!.
54 B. Efron and R. J. Tibshirani, An introduction to the Bootstrap ~Chapman
& Hall, New York, 1993!.
55 K. S. C. Chao, J. O. Deasy, J. Markman, J. Haynie, C. A. Perez, J. A.
Purdy, and D. A. Low, ‘‘A prospective study of salivary function sparing
in patients with head and neck cancers receiving intensity-modulated or
three-dimensional radiation therapy: initial results,’’ Int. J. Radiat. Oncol.,
Biol., Phys. 49, 907–916 ~2001!.
56 J. O. Deasy, J. Markman, and K. S. C. Chao, ‘‘Uncertainties in outcome
predictions for treatment planning,’’ Int. J. Radiat. Oncol., Biol., Phys.
49, 907–916 ~2001!.
57 J. Markman, J. O. Deasy, C. K. Chao, and D. Low, ‘‘Bioeffect modeling
of nonuniform dose distributions for paired organs,’’ Proceedings of the
World Congress on Medical Physics and Bioengineering, Chicago, IL,
2000 ~CD-ROM!.
58 J. H. Zar, Biostatistical Analysis ~Prentice–Hall, Englewood Cliffs, NJ,
1984!.
59 L. B. Marks et al., ‘‘The utility of SPECT lung perfusion scans in mini-
mizing and assessing the physiologic consequences of thoracic irradia-
tion,’’ Int. J. Radiat. Oncol., Biol., Phys. 26, 659–668 ~1993!.
60 J. F. Fowler, ‘‘Is repair of DNA strand break damage from ionizing ra-
diation second-order rather than first-order? A simple explanation of ap-
parently multiexponential repair,’’ Radiat. Res. 152, 124–136 ~1999!.
61 P. A. Canney and W. T. Millar, ‘‘Biphasic cellular repair and implications
for multiple field radiotherapy treatments,’’ Br. J. Radiol. 70, 817–822
~1997!.
62 J. O. Deasy, J. F. Fowler, J. L. Roti Roti, and D. A. Low, ‘‘Dose-rate
effects in intensity modulated radiation therapy,’’ Int. J. Radiat. Oncol.,
Biol., Phys. 51, 400–401 ~2001!.
63 J. Bijhold, ‘‘Three-dimensional verification of patient placement during
radiotherapy using portal images,’’ Med. Phys. 20, 347–356 ~1993!.
64 D. Yan, D. Jaffray, and J. Won, ‘‘A model to accumulate the fractionated
dose in a deforming organ,’’ Int. J. Radiat. Oncol., Biol., Phys. 44, 665–
675 ~1999!.
65 W. Lu, ‘‘A generalization of adaptive radiotherapy and the registration of
deformable dose distribution,’’ XIIIth International Conference on The
Use of Computers in Radiotherapy, Heidelberg, Germany, 2000.
66 J. Williamson, ‘‘A deformable template approach to registration of serial
CT studies for dose planning in intracavitary brachytherapy,’’ in Ref. 65.
67 J. Bijhold, J. V. Lebesque, A. M. Augustinus Hart, and R. E. Vijlbrirf,
‘‘Maximizing setup accuracy using portal images as applied to a confor-
mal boost technique for prostatic cancer,’’ Radiother. Oncol. 24, 261–271
~1992!.
68 D. Yan, D. Lockman, D. Brabbins, L. Tyburski, and A. Martinez, ‘‘An
off-line strategy for constructing a patient-specific planning target volume
for image guided adaptive radiotherapy of prostate cancer,’’ Int. J. Radiat.
Oncol., Biol., Phys. 48, 289–302 ~2000!.
69 D. Yan and D. Lockman, ‘‘Organ/patient positioning variation in external
beam radiotherapy and its effects,’’ Med. Phys. 28, 593–602 ~2001!.
70 J. Leong, ‘‘Implementation of random positioning error in computerized
radiation treatment planning systems as a result of fractionation,’’ Phys.
Med. Biol. 32, 327–334 ~1987!.
71 J. F. Fowler, ‘‘The linear-quadratic formula and progress in fractionated
radiotherapy,’’ Br. J. Radiol. 62, 679–694 ~1989!.Medical Physics, Vol. 29, No. 9, September 200272 G. W. Barensden, ‘‘Dose fractionation, dose rate and iso-effect relation-
ships for normal tissue response,’’ Int. J. Radiat. Oncol., Biol., Phys. 8,
1981–1997 ~1982!.
73 B. Emami, J. Lyman, A. Brown, L. Coia, M. Goitein, J. E. Munzenrider,
B. Shank, L. J. Solin, and M. Wesson, ‘‘Tolerance of normal tissue to
theraputic irradiation,’’ Int. J. Radiat. Oncol., Biol., Phys. 21, 109–122
~1991!.
74 H. Mameghan, R. Fisher, J. Mameghan, W. H. Watt, and A. Tynan,
‘‘Bowel complications after radiotherapy for carcinoma of the prostate:
The volume effect,’’ Int. J. Radiat. Oncol., Biol., Phys. 18, 315–320
~1990!.
75 D. P. Dearnaley, V. S. Khoo, A. R. Norman, L. Meyer, A. Nahum, D. Tait,
J. Yarnold, and A. Howwich, ‘‘Comparison of radiation side-effects of
conformal and conventional radiotherapy in prostate cancer: a ran-
domised clinical trial,’’ Lancet 353, 267–272 ~1999!.
76 V. A. Benk, J. A. Adams, W. U. Shipley, M. M. Urie, P. L. McManus, J.
T. Efrid, C. G. Willet, and M. Goitein, ‘‘Late rectal bleeding following
combined x-ray and proton high dose irradiation for patients with stages
T3–T4 prostate carcinoma,’’ Int. J. Radiat. Oncol., Biol., Phys. 26, 551–
557 ~1993!.
77 C. A. Lawton et al., ‘‘Long-term treatment sequelae following external
beam irradiation for adenocarcinoma of the prostate: analysis of RTOG
studies 7506 and 7706,’’ Int. J. Radiat. Oncol., Biol., Phys. 21, 935–939
~1991!.
78 A. C. Hartford, A. Niemierko, J. A. Adams, M. M. Urie, and W. U.
Shipley, ‘‘Conformal irradiation of the prostate: estimating long term
rectal bleeding using dose–volume histograms,’’ Int. J. Radiat. Oncol.,
Biol., Phys. 36, 721–730 ~1996!.
79 T. E. Schultheiss, W. R. Lee, M. A. Hunt, A. L. Hanlon, R. S. Peter, and
G. E. Hanks, ‘‘Late GI and GU complications in the treatment of prostate
cancer,’’ Int. J. Radiat. Oncol., Biol., Phys. 37, 3–11 ~1997!.
80 L. J. Boersma, M. van den Brink, A. M. Bruce, T. Shouman, L. Gras, A.
te Velde, and J. V. Lebesque, ‘‘Estimation of the incidence of late bladder
and rectum complications after high dose ~70–78 Gy! conformal radio-
therapy for prostate cancer, using dose–volume histograms,’’ Int. J. Ra-
diat. Oncol., Biol., Phys. 41, 83–92 ~1998!.
81 M. W. Skwarchuk, A. Jackson, M. J. Zelefsky, E. S. Venkatraman, D. M.
Cowen, S. Levegrun, C. M. Burman, Z. Fuks, S. A. Leibel, and C. C.
Ling, ‘‘Late rectal toxicity after conformal radiotherapy of prostate can-
cer ~I!: Multivariate analysis and dose-response,’’ Int. J. Radiat. Oncol.,
Biol., Phys. 47, 103–113 ~2000!.
82 A. Jackson, M. W. Skwarchuk, M. J. Zelefsky, D. M. Cowen, E. S.
Venkatraman, S. Levegrun, C. M. Burman, G. J. Kutcher, Z. Fuks, S. A.
Leibel, and C. C. Ling, ‘‘Late rectal bleeding after conformal radio-
therapy of prostate cancer ~II!: volume effects and dose volume histo-
grams,’’ Int. J. Radiat. Oncol., Biol., Phys. 49, 685–698 ~2001!.
83 A. Jackson, M. W. Skwarchuk, and S. Levegrun, ‘‘Volume effects in
external beam treatments of prostate cancer’’ ~extended abstract!, in ~Pro-
ceedings of the 5th International Symposium on 3D Conformal Radiation
Therapy and Brachytherapy, edited by H. I. Amols and H. J. Zelefsky,
Memorial Sloan–Kettering Cancer Center, New York, NY, 1–3 June
2000.
84 J. D. Fenwick, V. S. Khoo, A. E. Nahum, B. Sanchez-Nieto, and D. P.
Dearnaley, ‘‘Correlations between dose–surface histograms and the inci-
dence of long-term rectal bleeding following conformal or conventional
radiotherapy treatment of prostate cancer,’’ Int. J. Radiat. Oncol., Biol.,
Phys. 49, 473–480 ~2001!.
85 L. J. Boersma, E. M. Damen R. W. de Boer, S. H. Muller, R. A. Valdes
Olmos, C. A. Hoefnagel, C. M. Roos, N. van Zandwijk, and J. V. Leb-
esque, ‘‘A new method to determine dose-effect relations for local lung-
function changes using correlated SPECT and CT data,’’ Radiother. On-
col. 29, 110–116 ~1993!.
86 L. B. Marks, M. T. Munley, D. P. Spencer, G. W. Sherouse, G. C. Bentel,
J. Hoppenworth, M. Chew, R. J. Jaszczak, R. E. Coleman, and L. R.
Prosnitz, ‘‘Quantification of radiation-induced regional lung injury with
perfusion imaging,’’ Int. J. Radiat. Oncol., Biol., Phys. 38, 399–409
~1997!.
87 L. B. Marks, D. Hollis, M. Munley, G. Bentel M. Garipagaoglu, M. Fan,
J. Poulson, R. Clough, G. Sibley, R. E. Coleman, and R. Jaszczak, ‘‘The
role of lung perfusion imaging in predicting the direction of radiation-
induced changes in pulmonary function tests,’’ Can. Mineral. 88, 2135–
2141 ~2000!.
88 Y. Seppenwoolde, S. H. Muller, J. C. Theuws, P. Baas, J. S. Belderbos, L.
2126 Deasy et al.: Methodological issues in radiation dose-volume outcome analyses 2126J. Boersma, and J. V. Lebesque, ‘‘Radiation dose-effect relations and
local recovery in perfusion for patients with non-small-cell lung cancer,’’
Int. J. Radiat. Oncol., Biol., Phys. 47, 681–690 ~2000!.
89 J. M. Balter, R. K. Ten Haken, T. S. Lawrence, K. L. Lam, and J. R.
Robertson, ‘‘Uncertainties in CT-based treatment plans due to patient
breathing,’’ Int. J. Radiat. Oncol., Biol., Phys. 36, 167–174 ~1996!.
90 J. G. Armstrong, M. J. Zelefsky, S. A. Leibel, C. Burman, C. Han, L. B.
Harrison, G. J. Kutcher, and Z. Y. Fuks, ‘‘Strategy for dose escalation
using 3-dimensional conformal radiation therapy for lung cancer,’’ Ann.
Oncol. 6, 693–697 ~1995!.
91 L. A. Dawson, C. McGinn, D. Normolle, R. K. Ten Haken, W. Ens-
minger, and T. S. Lawrence, ‘‘Escalated focal liver radiation and hepatic
artery fluorodeoxyuridine for unresectable liver malignancies,’’ J. Clin.
Oncol. 18, 2210–2218 ~2000!.
92 L. A. Dawson, R. K. Ten Haken, and T. S. Lawrence, ‘‘Partial irradiation
of the liver,’’ Semin Radiat. Oncol. 11, 234–239 ~2001!.
93 M. V. Graham, J. A. Purdy, B. Emami, J. W. Matthews, and W. B. Harms,
‘‘Preliminary results of a prospective trial using three dimensional radio-
therapy for lung cancer,’’ Int. J. Radiat. Oncol., Biol., Phys. 33, 993–
1000 ~1995!.
94 J. A. Hayman, M. K. Martel, R. K. Ten Haken, D. P. Normolle, R. F. Todd
III, J. F. Littles, M. A. Sullivan, P. W. Possert, A. T. Turrisi, and A. S.
Lichter, ‘‘Dose escalation in non-small cell lung cancer using
3-dimensional conformal radiation therapy: update of a phase I trial,’’ J.
Clin. Oncol. 19, 127–136 ~2001!.
95 B. L. Kwa, J. V. Lebesque, J. C. Theuws, L. B. Marks, M. T. Munley, G.
Bentel, D. Oetzel, U. Spahn, M. V. Graham, R. E. Drzymala, J. A. Purdy,
A. S. Lichter, M. K. Martel, and R. K. Ten Haken, ‘‘Radiation pneumoni-
tis as a function of mean lung dose: an analysis of pooled data of 540
patients,’’ Int. J. Radiat. Oncol., Biol., Phys. 42, 1–9 ~1998!.
96 L. B. Marks, M. Fan, R. Clough, M. Munley, G. Bentel, R. E. Coleman,
R. Jaszczak, D. Hollis, and M. Anscher, ‘‘Radiation-induced pulmonary
injury: symptomatic versus subclinical endpoints,’’ Int. J. Radiat. Oncol.,
Biol., Phys. 76, 469–475 ~2000!.
97 M. K. Martel, Ten Haken, M. B. Hazuka, A. T. Turrisi, B. A. Fraass, and
A. S. Lichter, ‘‘Dose–volume histogram and 3-D treatment planning
evaluation of patients with pneumonitis,’’ Int. J. Radiat. Oncol., Biol.,
Phys. 28, 575–581 ~1994!.
98 C. J. McGinn, R. K. Ten Haken, W. D. Ensminger, S. Walker, S. Wang,
and T. S. Lawrence, ‘‘The treatment of intrahepatic cancers with radiation
doses based on a normal tissue complication probability model,’’ J. Clin.
Oncol. 16, 2246–2252 ~1998!.
99 D. Oetzel, P. Schraube, F. Hensley, G. Sroka-Perez, M. Menke, and M.
Flentje, ‘‘Estimation of pneumonitis risk in three-dimensional treatment
planning using dose-volume histogram analysis,’’ Int. J. Radiat. Oncol.,
Biol., Phys. 33, 455–460 ~1995!.
100 J. M. Robertson, R. K. Ten Haken, A. T. Turrisi, M. B. Hazuka, M. K.
Martel, J. F. Littles, F. J. Martinez, I. Francis, L. Quint, and A. S. Lichter,
‘‘Dose escalation for non-small cell lung cancer using conformal radia-
tion therapy,’’ Int. J. Radiat. Oncol., Biol., Phys. 37, 1079–1085 ~1997!.
101 A. Jackson, C. C. Ling, C. M. Burman, E. S. Venkatraman, J. Bass, A.
Raben, S. A. Leibel, and Z. Fuks, ‘‘A conformal dose escalation protocol
for the treatment of tumors in the lung or other normal tissues with
parallel architecture,’’ Med. Phys. 23, 1495 ~1996!.
102 R. K. Ten Haken, M. K. Martel, M. L. Kessler, M. B. Hazuka, T. S.
Lawrence, J. M. Robertson, A. T. Turrisi, and A. S. Lichter, ‘‘Use of Veff
and iso-NTCP in the implementation of dose escalation protocols,’’ Int. J.
Radiat. Oncol., Biol., Phys. 27, 689–695 ~1993!.
103 A. Jackson, R. K. Ten Haken, J. M. Robertson, M. L. Kessler, G. J.
Kutcher, and T. S. Lawrence, ‘‘Analysis of clinical complication data for
radiation hepatitis using a parallel architecture model,’’ Int. J. Radiat.
Oncol., Biol., Phys. 31, 883–891 ~1995!.
104 S. A. Roberts and J. H. Hendry, ‘‘The delay before onset of accelerated
tumour cell repopulation during radiotherapy: a direct maximum-
likelihood analysis of a collection of worldwide tumour-control data,’’
Radiother. Oncol. 29, 69–74 ~1993!.
105 R. K. Ten Haken, T. S. Lawrence, D. L. McShan, R. J. Tesser, B. A.
Fraass, and A. S. Lichter, ‘‘Technical considerations in the use of 3-D
beams in the abdomen,’’ Radiother. Oncol. 22, 19–28 ~1991!.
106 T. S. Lawrence, R. J. Tesser, and R. K. Ten Haken, ‘‘An application of
dose volume histograms to treatment of intrahepatic malignancies with
radiation,’’ Int. J. Radiat. Oncol., Biol., Phys. 19, 1041–1047 ~1990!.
107 T. S. Lawrence, L. M. Dworzanin, S. C. Walker-Andrews, J. C. Andrews,Medical Physics, Vol. 29, No. 9, September 2002R. K. Ten Haken, I. S. Wollner, A. S. Lichter, and W. D. Ensminger,
‘‘Treatment of cancers involving the liver and porta hepatis with external
beam irradiation and intraarterial hepatic fluorodeoxyuridine,’’ Int. J. Ra-
diat. Oncol., Biol., Phys. 20, 555–561 ~1991!.
108 J. T. Lyman, ‘‘Complication probability as assessed from dose volume
histograms,’’ Radiat. Res. 104, S13–S19 ~1985!.
109 T. S. Lawrence, R. K. Ten Haken, M. L. Kessler, J. M. Robertson, J. T.
Lyman, M. L. Lavigne, M. B. Brown, D. J. DuRoss, J. C. Andrews, W. D.
Ensminger, and A. S. Lichter, ‘‘The use of 3-D dose volume analysis to
predict radiation hepatitis,’’ Int. J. Radiat. Oncol., Biol., Phys. 23, 781–
788 ~1992!.
110 G. J. Kutcher and C. Burman, ‘‘Calculation of complication probability
factors for nonuniform normal tissue irradiation: the effective volume
method,’’ Int. J. Radiat. Oncol., Biol., Phys. 16, 1623–1630 ~1989!.
111 J. Hanley, M. M. Debois, D. Mah, G. S. Mageras, A. Raben, K. Rosen-
zweig, B. Mychalczak, L. H. Schwartz, P. J. Gloeggler, W. Lutz, C. C.
Ling, S. A. Leibel, Z. Fuks, and G. J. Kutcher, ‘‘Deep inspiration breath-
hold technique for lung tumors: the potential value of target immobiliza-
tion and reduced lung density in dose escalation,’’ Int. J. Radiat. Oncol.,
Biol., Phys. 45, 603–611 ~1999!.
112 J. W. Wong, M. B. Sharpe, D. A. Jaffray, V. R. Kini, J. M. Robertson, J.
S. Stromberg, and A. A. Martinez, ‘‘The use of active breathing control
~ABC! to reduce margin for breathing motion,’’ Int. J. Radiat. Oncol.,
Biol., Phys. 44, 911–919 ~1999!.
113 J. M. Balter, K. L. Lam, C. J. McGinn, T. S. Lawrence, and R. K. Ten
Haken, ‘‘Improvement of CT-based treatment planning models of ab-
dominal targets using static exhale imaging,’’ Int. J. Radiat. Oncol., Biol.,
Phys. 41, 939–943 ~1998!.
114 R. K. Ten Haken, J. M. Balter, L. H. Marsh, J. M. Robertson, and T. L.
Lawrence, ‘‘Potential benefits of eliminating planning target volume ex-
pansions for patient breathing in the treatment of liver tumors,’’ Int. J.
Radiat. Oncol., Biol., Phys. 38, 613–617 ~1997!.
115 A. E. Lujan, E. W. Larsen, J. M. Balter, and R. K. Ten Haken, ‘‘A method
for incorporating organ motion due to breathing into 3D dose calcula-
tions,’’ Med. Phys. 26, 715–720 ~1999!.
116 A. E. Lujan, R. K. Ten Haken, E. W. Larsen, and J. M. Balter, ‘‘Quanti-
zation of setup uncertainties in 3D dose calculations,’’ Med. Phys. 26,
2397–2402 ~1999!.
117 N. Choi, J. E. Herndon II, J. Rosenmann, R. W. Carey, C. T. Chung, S.
Bernard, L. Leone, S. Seagren, and M. Green, ‘‘Phase I study to deter-
mine the maximum-tolerated dose of radiation in standard daily and
hyperfractioned-accelerated twice-daily radiation schedules with concur-
rent chemotherapy for limited stage small-cell lung cancer,’’ J. Clin. On-
col. 16, 3528–3537 ~1998!.
118 C. R. Thomas, Jr., D. J. Giroux, K. J. Stelzer, J. B. Craig, L. R. Laufman,
S. A. Taylor, J. W. Goodwin, J. J. Crowley, and R. B. Livingston, ‘‘Con-
current cisplatin prolonged oral etoposide, and vincristine plus chest and
brain irradiation for limited small cell lung cancer: A phase II study of the
southwest oncology group ~SWOG-9229!,’’ Int. J. Radiat. Oncol., Biol.,
Phys. 40, 1045–1047 ~1998!.
119 M. V. Graham, ‘‘Predicting radiation response,’’ Int. J. Radiat. Oncol.,
Biol., Phys. 39, 561–562 ~1997!.
120 L. Marks, M. T. Munley, G. C. Bentel, S.-M. Zhou, D. Hollis, C. Scar-
fone, G. S. Sibley, F.-M. Kong, R. Jirtle, R. Jaszczak, R. E. Coleman, V.
Tapson, and M. Anscher, ‘‘Physical and biological predictors of changes
in whole lung function following thoracic irradiation,’’ Int. J. Radiat.
Oncol., Biol., Phys. 39, 563–570 ~1997!.
121 M. V. Graham, J. A. Purdy, B. Emami, W. Harms, W. Bosch, M. A.
Lockett, and C. A. Perez, ‘‘Clinical dose–volume histogram analysis for
pneumonitis after 3D treatment for non-small cell lung cancer
~NSCLC!,’’ Int. J. Radiat. Oncol., Biol., Phys. 45, 323–329 ~1999!.
122 M. Langer and P. Kijewski, ‘‘CCRT for non-small cell lung cancer: sen-
sitivity of clinical gains to organ tolerance restrictions,’’ Int. J. Radiat.
Oncol., Biol., Phys. 22, 325–332 ~1992!.
123 C. Ha, P. J. Kijewski, and M. P. Langer, ‘‘Gain in target dose from
using computer controlled radiotherapy ~CCRT! in the treatment of non-
small cell lung cancer.’’ Int. J. Radiat. Oncol., Biol., Phys. 26, 335–356
~1991!.
124 M. V. Graham, J. A. Purdy, B. Emami, W. Harms, W. Bosch, M. A.
Lockett, and C. A. Perez, ‘‘Clinical dose–volume histogram analysis for
pneumonitis after 3D treatment for non-small lung cancer,’’ Int. J. Radiat.
Oncol., Biol., Phys. 45, 323–329 ~1999!.
2127 Deasy et al.: Methodological issues in radiation dose-volume outcome analyses 2127125 M. Langer, P. Kijewski, R. Brown, and C. Ha, ‘‘The effect on minimum
tumor dose of restricting target-Dose inhomogeneity in optimized three-
dimensional treatment of lung cancer,’’ Radiother. Oncol. 21, 245–256
~1991!.
126 M. V. Graham, J. W. Mathews, W. B. Harms, B. Emami, H. S. Glazer,
and J. A. Purdy, ‘‘Three-dimensional radiation treatment planning study
for patients with carcinoma of the lung,’’ Int. J. Radiat. Oncol., Biol.,
Phys. 29, 1105–1117 ~1994!.
127 H. H. Liu, I. I. Rosen, N. A. Janjan, and A. Pollack, ‘‘Treatment planning
optimization based on response-surface modeling of cost function versusMedical Physics, Vol. 29, No. 9, September 2002multiple constraints,’’ CD-ROM Proceedings of the World Congress on
Medical Physics and Biomedical Engineering, 23–28 July 2000.
128 M. Langer, V. Thai, and L. Papiez, ‘‘Sensitivity analysis of tolerance
limits for dose-escalation,’’ in Ref. 127.
129 M. Langer, S. Morrill, and R. Lane, ‘‘A test of the claim that plan rank-
ings are determined by relative complication and tumor control probabili-
ties,’’ Int. J. Radiat. Oncol., Biol., Phys. 41, 451–457 ~1998!.
130 G. B. Dantzig, in ‘‘Convex programming,’’ Linear Programming and
Extensions ~Princeton University Press, Princeton, NJ!, Chap. 24, pp.
471–498.
131 E. Fermi, ‘‘The nucleus’’ Phys. Today 5, 6–9 ~1952!.
